+

WO1998015830A2 - Homogenous luminescence energy transfer assays - Google Patents

Homogenous luminescence energy transfer assays Download PDF

Info

Publication number
WO1998015830A2
WO1998015830A2 PCT/FI1997/000560 FI9700560W WO9815830A2 WO 1998015830 A2 WO1998015830 A2 WO 1998015830A2 FI 9700560 W FI9700560 W FI 9700560W WO 9815830 A2 WO9815830 A2 WO 9815830A2
Authority
WO
WIPO (PCT)
Prior art keywords
acceptor
donor
energy transfer
assay
label
Prior art date
Application number
PCT/FI1997/000560
Other languages
French (fr)
Other versions
WO1998015830A3 (en
Inventor
Ilkka Antero HEMMILÄ
Pertti Juhani Hurskainen
Kaj Runar Blomberg
Veli-Matti Mukkala
Harri Juha Takalo
Satu Anneli Kovanen
Stuart Alan Webb
Original Assignee
Wallac Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wallac Oy filed Critical Wallac Oy
Priority to JP10517208A priority Critical patent/JP2001502055A/en
Priority to EP97919087A priority patent/EP0929810A2/en
Publication of WO1998015830A2 publication Critical patent/WO1998015830A2/en
Publication of WO1998015830A3 publication Critical patent/WO1998015830A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
    • G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
    • G01N21/64—Fluorescence; Phosphorescence
    • G01N21/6408—Fluorescence; Phosphorescence with measurement of decay time, time resolved fluorescence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6816—Hybridisation assays characterised by the detection means
    • C12Q1/6818—Hybridisation assays characterised by the detection means involving interaction of two or more labels, e.g. resonant energy transfer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
    • G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
    • G01N21/64—Fluorescence; Phosphorescence
    • G01N21/6428—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes"
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/542—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G01N33/743—Steroid hormones
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G01N33/76—Human chorionic gonadotropin including luteinising hormone, follicle stimulating hormone, thyroid stimulating hormone or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
    • G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
    • G01N21/64—Fluorescence; Phosphorescence
    • G01N21/6428—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes"
    • G01N2021/6439—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes" with indicators, stains, dyes, tags, labels, marks
    • G01N2021/6441—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes" with indicators, stains, dyes, tags, labels, marks with two or more labels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2458/00—Labels used in chemical analysis of biological material
    • G01N2458/40—Rare earth chelates

Definitions

  • the present invention relates to improvements of energy- transfer based homogeneous assays, which use time-resolved fluorometry in detection.
  • the specific improvements relate to the type of lanthanide chelate labels used as energy donors, optimized energy acceptors for defined assays, the way energy transfer is measured using optimized filters and time windows, ways to correct all possible interferences derived from samples, use the assay for multi-component analysis and development of simplified assay protocols.
  • assays based on bioaffinity or enzymatically catalysed reactions have been developed to analyze biologically important compounds from various biological samples (such as serum, blood, plasma, saliva, urine, feces , seminal plasma, sweat, liquor, amniotic fluid, tissue homogenate, ascites, etc.), samples in environmental studies (waste water, soil samples) industrial processes (process solutions, products) and compound libraries (screening libraries which may comprise organic compounds, inorganic compounds, natural products, extracts of biological sources, biological proteins, peptides, or nucleotides, and so on).
  • biological samples such as serum, blood, plasma, saliva, urine, feces , seminal plasma, sweat, liquor, amniotic fluid, tissue homogenate, ascites, etc.
  • samples in environmental studies waste water, soil samples
  • industrial processes process solutions, products
  • compound libraries screening libraries which may comprise organic compounds, inorganic compounds, natural products, extracts of biological sources, biological proteins, peptides, or nucleotides,
  • Some of these assays rely on specific bioaffinity recognition reactions, where generally natural biological binding components are used to form the specific binding assay (with biological binding components such as antibodies, natural hormone binding proteins, lectins , enzymes, receptors, DNA, RNA or PNA) or artificially produced binding compounds like genetically or chemically engineered antibodies, molded plastic imprint (molecular imprinting) and so on.
  • Such assays generally rely on a label to quantitate the formed complexes after recognition and binding reaction and suitable separation (separations like precipitation and centrifugation, filtration, affinity collection to e.g. plastic surfaces such as coated assay tubes, slides of microbeads, solvent extraction, gel filtration or other chromatographic systems, and so on).
  • the quantitation of the label in free or bound fraction enables the calculation of the analyte in the sample directly or indirectly, generally through use of a set of standards to which unknown samples are compared.
  • Time-resolved fluorometry (time resolution in time-domain at micro- or millisecond range) is a perfect measuring regime for homogeneous assays, because it can totally discriminate the background fluorescence derived from organic compounds when long enough delay times (time between pulsed excitation and starting of emission recording) are used (for a review see. e.g. Hemmila (1991); Gudgin Dickinson et al, (1995) J Photochem Photobiol 27, 3).
  • delay times time between pulsed excitation and starting of emission recording
  • the aim of the present invention is i.a. to provide an improvement in time- resolved homogeneous assay principle based on specific energy transfer between a long life-time chelate-based donor probe and short life-time (or non-emitting) acceptor molecule.
  • r is the distance between the donor and acceptor molecules and R 0 is a distance parameter characteristic of the donor-acceptor pair and the medium between them.
  • Fluorescence resonance energy transfer has been applied e.g. as an spectroscopic ruler in structural studies to measure distances within a macromolecule (Stryer and Haugland (1967) Proc Natl Acad Sci, USA, 58; 719).
  • resonance energy transfer there are also other energy transfer reactions, like simple radiative (where acceptor absorbs the light emitted by donor), collisional energy transfer, exchange (Dexter (1953) J Chem Physics, 21, 836) and exciton migration (in crystals).
  • the donor emission can be quenched by numerous ways with a number of unrelated compounds having an deactivating effect on some of the donor's energy levels.
  • FETIA primarily applies xanthene dyes and derivatives of fluorescein as donor and rhodamines as acceptors .
  • a great number of alternative probe pairs have since been developed and applied in immunoassays (for a review see Hemmila 1991, chapter 8.3.4) including practically non-fluorescent derivatives of fluorescein, long life-time delayed fluorescence emittive eosin (Thakrar and Miller (1982) Anal Proc, 19, 329), long lifetime fluorescent pyrene (Morrison (1988) Anal Biochem, 174, 101) and non-e ittive charcoal.
  • FRET has since got wide applications in basic research and in DNA hybridizations (see e.g. Morrison et al (1989) Anal Biochem, 183, 231; Parkhurst et al (1995) Biochemistry, 34, 285) and other assays were association, dissociation or distances are to be measured.
  • temporal discrimination time-resolution
  • organic donor-acceptor pairs of different decay times using pyrene as the long excited state donor, pulsed laser for excitation and phycoerythrin as the short decay-time acceptor (US 4,822,733).
  • time-resolved energy transfer principle is applied for homogeneous solution hybridization using fluorescein (Morrison et al (1989) Illrd International Symposium on Quantitative Luminescence Spectrometry in Biomedical Sciences, Ghent Belgium) as acceptor.
  • the long excited state provides the advantage, that specific energy transfer can be followed using a delay time, during which the emission of directly excited acceptor is decayed off.
  • the combination of different decay times exploited in time- resolved fluorometry will provide a clear advantage over FRET technologies employing conventional short decay probes .
  • Luminescent (fluorescent) lanthanides have long been used as tools for DNA and protein structural studies (See e.g. Brittain (1985) Bioinorganic Luminescence Spectroscopy, Schulman (ed), Molecular Luminescence Spectroscopy, Wiley, NY; B ⁇ nzli and Choppin (1989) Lanthanide Probes in Life, Chemical and Earth Sciences, Theory and Practice, Elsevier Science Publisher, Amsterdam), applied e.g. for RNA, ribosomes, DNA and chromatin, termolysin and transferrin, calmodulin, ATPase, nerve membranes, erythrocyte membrane proteins, phospholipids and liposomes and their fusions (for an review see Hemmila 1991).
  • Lanthanides and their chelates are good candidates for time-resolved FRET experiments. Firstly, they have exceptionally long excited state lifetime (Weissman (1942) Chem Phys, 10, 214; Whan and Crosby (1962) Mol Spectrosc, 8, 315). The energy transfer takes place only between transitions that are electric dipole. The major transition in the highly fluorescent Eu chelates, (transition D 0 - 7 F 2 ) at 612-620 n is electric dipole "forced" (B ⁇ nzli (1989) Lanthanide Probes in Life, Chemical and Earth Sciences. Theory and Practice, B ⁇ nzli and Choppin (ed) Elsevier Science, Publisher, Amsterdam) and can donate energy.
  • transition D 0 - F x producing emission at 590-595 nm is, however, magnetic dipole and can not transfer energy (Dexter, J Chem Phys 21? 836, 1953).
  • lanthanide emission has isotropic dipolic moment, and hence the orientation factor becomes less ambiguous (Ando et al
  • Fluorescent lanthanide chelates have been used as energy donors already since 1978 by Stryer, Thomas and Meares.
  • a Tb dipicolinate chelate reported to have the critical distance (R 0 ) of 6.57 nm for rhodamine, 4.46 nm for eosin and 4.46 nm for NBD (Thomas et al (1978) Proc Natl Acad Sci, 75; 5746).
  • R 0 critical distance
  • the overall decay shortens, as shown in the above system, from 2.22 ms to 0.12 ms .
  • the preferred chelate is composed of nona-dentate chelating ligand, such as terpyridine (EP-A 403593; US 5,324,825; US 5,202,423, US 5,316,909), terpyridine analogue with one or two five-membered rings (e.g. pyrazole, thiazole, triazine) (US Appl 08/548,174 and PCT/FI91/00373) .
  • terpyridine EP-A 403593; US 5,324,825; US 5,202,423, US 5,316,909
  • terpyridine analogue with one or two five-membered rings e.g. pyrazole, thiazole, triazine
  • Very well suited chelates are also mentioned in following articles (Takalo et al (1994)
  • Hoffman La Roche has patented a specific application using lumazine-t pe of chromophore as donor and a ruthenium chelate as acceptor for interactions between nucleic acids (EP 439036) and Cis Bio International applied for an assays based on Eu or Tb cryptates as donors for phycobiliproteins (WO 92/01225) .
  • the principle of a time-resolved homogeneous assay based on a specific energy transfer between a long-life time donor and a short life-time emitting acceptor molecule can be summarized as follows:
  • the emission duration of a short excited state acceptor, excited during the excited lifetime of a long-decay time donor through the mechanism of energy transfer, is longer than the decay time of the directly excited acceptor. This fact permits the use of temporal discrimination (time-resolution) to avoid the luminescence from directly excited acceptor.
  • A light pulse
  • the luminescence emission of the energy-transfer excited acceptor is measured (D) after a suitable delay (C), to avoid interference derived from directly excited acceptor (B).
  • the long-lived emission from the donor (DE) is avoided by measuring the emission of the energy-transfer excited acceptor (AE) at a wavelength where the donor emission is absent or negligible ( Figure 2).
  • AE emission of the energy-transfer excited acceptor
  • An object of the present invention is to provide a luminescence energy transfer assay comprising a first group labelled with an energy donor and a second group labelled with an energy acceptor, wherein the acceptor is either a short excited state lifetime luminescent label or a non- luminescent label.
  • the donor is a luminescent lanthanide chelate.
  • the assay is based on a reaction resulting in lengthening of the distance between the labelled donor and acceptor groups .
  • the donor luminescent lanthanide chelate has a long excited state lifetime.
  • the assay is based on a reaction resulting in either shortening or lengthening of the distance between the labelled donor and acceptor groups and the donor is a luminescent lanthanide chelate having a long excited state lifetime.
  • the long excited state lifetime luminescent lanthanide chelate has one or more of the following properties:
  • two or more analytes are simultaneously measured, wherein each analyte is measured by a specific donor-acceptor pair.
  • the luminescent or non-luminescent label of the acceptor is attached to a solid carrier providing a large surface to which said second group is bound or can be bound via suitable covalent or non-covalent means.
  • the acceptor is lipophilic compound anchored to a cell membrane or cell membrane fragment or the acceptor is made lipophilic by conjugating with a long chain hydrocarbon such as a fatty acid.
  • the instrument used to measure energy transfer is able to follow multiple parameters simultaneously or consecutely, such as absorbances at the wavelenghts of excitation or emissions, luminescence of different durations, scattering and luminescence decay times, in order to monitor and correct any interferences the sample matrix may have to excitation, energy transfer or emissions.
  • Figure 1 shows the luminescence versus time after donor excitation with a light pulse (A) of directly excited acceptor (B) and the luminescence emission of the energy- transfer excited acceptor (D) after a suitable delay (C).
  • Figure 2 shows the luminescence intensity versus emission wavelength of donor (DE) and acceptor (AE).
  • Figure 3 shows a standard curve for the homogenous energy transfer assay of BhCG ( ⁇ -subunit of human chorionic gonadotropin) .
  • Figure 4 shows a standard curve for the homogenous energy transfer assay of PSA (prostate specific antigen).
  • Figure 5 shows a standard curve for the homogenous energy transfer assay of ⁇ hCG using indirect labelling.
  • Figure 6 shows a standard curve for the homogenous energy transfer assay of ⁇ hCG using indirect labelling and an acceptor different from that of Figure 5.
  • the present invention relates to improvements of energy- transfer based homogeneous assays, which use time-resolved fluorometry in detection.
  • the specific improvements relate to the type of lanthanide chelate labels used as energy donors, optimized energy acceptors for defined assays, the way energy transfer is measured using optimized filters and time windows, ways to correct all possible interferences derived from samples, use the assay for multi-component analysis and development of simplified assay protocols.
  • first group and second group shall be understood to include any component such as bioaffinity recognition component (in reactions where the distance between the groups decreases, e.g. in bioaffinity reactions) or a part of a molecule or substrate (e.g. the distal ends of a peptide molecule the cleavage of which will separate the two labelled groups from each other).
  • bioaffinity recognition component in reactions where the distance between the groups decreases, e.g. in bioaffinity reactions
  • substrate e.g. the distal ends of a peptide molecule the cleavage of which will separate the two labelled groups from each other.
  • luminescence shall cover fluorescense, phosphorescence, chemiluminescence, bioluminescence and electro-generated luminescence, photoluminescence, radioluminescence, sonoluminescence, thermoluminescence and triboluminescence .
  • a preferred arrangement in assays, where association is to be measured is to use luminescent, short decay time acceptor and long decay time lanthanide chelate based donor and follow the emission of acceptor molecule using a delay time in the time-resolved fluorometry to avoid the interference of acceptors direct luminescence (emanating from direct excitation of acceptor). It is desirable to construct the assay in a way that acceptor molecules are in excess (with time-resolved mode, their interference is negligible) and the association of binding reagents creates an increase in signal.
  • the preferred chelate label has to have high luminescence yield ( Ex ⁇ >2000), long excited state lifetime (preferably over 1 ms ) and emission distribution optimized for energy transfer.
  • the ligand field around the chelated ion has to be such that e.g. with Eu chelates over 70 % of emission is at D 0 - F 2 (at 610 - 620 nm range) and not at 590 nm range (compare e.g. emissions of Eu cryptate, WO 92/01225 and those of bis-iminoacetate derivatives of terpyridines, US 5,324,825; US 5,202,423 and US 5,316,909).
  • chelates In preferred chelates the useless magnetic dipole transition at 590 nm and emission around 700 nm are suppressed (Li and Selvin, J Amer Chem Soc 117; 8132, 1995).
  • Particularly good chelates for the present application are Eu chelates formed with multichromogenic polycarboxylates, having high molar absorption coefficient (G), very long excited state lifetime and good quantum yield ( ⁇ ) (Takalo et al . Helv Chim Acta 79; 789, 1996).
  • G molar absorption coefficient
  • ⁇ quantum yield
  • Tb is particularly promising energy donor, when its highly luminescent chelates are used.
  • a preferred Tb chelate is composed of terpyridine derivatives containing the binding side at the iminodiacetate group (Mukkala et al, J Alloys Compounds 225; 507, 1995) or otherwise a binding arm well isolated from the light absorbing aromatic structure.
  • Particularly good chelates for that applications are terpyridine derivatives where one or two pyridine rings are replaced with pyrazole (US 08/548,174) or triazole and thiazole rings (PCT/FI91/00373 ) .
  • the use of S would give the possibility to make double- or triple-label homogeneous energy transfer assays.
  • Sm has the advantage, that it can donate energy at a rather high wavelength, the major emission of a highly luminescent chelate being at 643 nm, giving the opportunity to continue with the wavelength scale up to near IR (a good collection of near-IR emitting fluors have become commercially available from different sources).
  • a preferred stable chelate of Sm is composed of multiple forms of 1 , 3-diketones , such as described by Savitsky (Savitsky et al, SPIE 2388; 429, 1995).
  • An alternative third choice (third label) is the phosphorescent Pt or Pd coproporphyrins emitting a long lifetime phosphorescence at 650-660 nm (WO 94/10568) .
  • a particularly preferred group of long excited state lifetime lanthanide chelates are Compounds 1 to 12 the structure of which is dislosed in Scheme 1 to 5.
  • ⁇ exc means excitation wavelength, ⁇ decay time and G x ⁇ luminescence yield.
  • the values given in the schemes are measured from the compound coupled to a protein. 98/15830
  • a preferred acceptor molecule for association assay is highly luminescent (with quantum yield as near unity (1) as possible) with high molar absorption coefficient (preferably over 100 000).
  • the absorption of the acceptor has to overlap with the energy-donating emission of donor, i.e. at 611-620 nm for Eu, 545 nm for Tb, 643 nm for Sm.
  • a preferred feature of the acceptor is its sharp emission at a wavelength where donor does not have any emission (such as 574-575 nm for Tb, 660-670 nm for Eu and around 675 for Sm) .
  • the decay-time of the acceptor should be below l ⁇ s .
  • the acceptor has to be attached to binding partners, either directly or indirectly (e.g.
  • covalently conjugated probes e.g. those of xanthene dyes (rhodamine, tetramethylrhodamine, Texas
  • a good acceptor for Eu should have absorption maximum at 611-620 nm range. Good acceptor for that wavelength range can be found particularly from the group of IR emittive dyes (for reviews see Haugland Molecular Probes, Miller, Spectroscopy Europe 5; 34, 1993, Patonay and Antoine, Anal Chem 63; 332A, 1991, Southwick et al, Cytometry 11; 418, 1990, Mujumbar et al, Cytometry 10; 11, 1989 and Mujumbar et al, Bioconjugate Chem 4; 105, 1993, Papkovsky, Appl Fluorescence Technol III; 16, 1991, Schindele and Renzoni, J Clin Immunoassay 13; 182, 1993).
  • phthalocyanines phthalocyanines
  • porphyrins cyanine dyes
  • cyanine dyes Cy-5, Cy5,18, Cy5,29
  • rhodamine 800 conjugated xanthenes
  • squarates Chang, EP176,252
  • methylene blue, Nile blue and oxazines Imasaka et al, Anal Chem 61; 2285, 1989
  • indocyanine green Imasaka et al, Anal Chem 62; 363A, 990.
  • phycobiliproteins are good candidates also for Eu acceptors, particularly A- PC, C-PC and R-PC .
  • a preferred energy acceptor for Sm or for coproporphyrins are the IR emittive dyes (see reviews mentioned above).
  • a preferred way to ascertain small distances between donor probe labelled ligand or binding reagent and acceptor probe labelled binding reagent is to use activated probes coupled directly to binding reagent (e.g. acceptor labelled receptor protein, antibody or other binding protein).
  • binding reagent e.g. acceptor labelled receptor protein, antibody or other binding protein.
  • An alternative way is to use indirect labelling, using e.g. anti-binder (such as anti-receptor) antibodies labelled with the acceptor, use of biotinylated binder and acceptor labelled ( strept )avidin or to employ other bioaffinity reactions to bring acceptor molecules in the vicinity of actual binding site, where the donor-labelled component either directly or indirectly will be bound.
  • a preferred way with impure, membrane-bound receptors is to use lipophilic membrane probes and stain all the membranes near or around the receptor with acceptor molecules .
  • Suitable probes attached to long aliphatic hydrocarbon chain such as e.g. oxacarbocyanine (Molecular Probes) are suitable for such staining.
  • Suitable solid carriers can be e.g. beads or particles with a diameter up to 1500 ⁇ m or any solid surface.
  • Microbeads labelled with a wide variety of luminescent probes are available from different sources.
  • a preferred probe used in the carrier is a hydrophobic compound, having negligible solubility to water to avoid leakage.
  • a variety of probes suitable for such labelling can be found amongst scintillator and laser dyes .
  • the great number of acceptor molecules may compensate the long distance after bead coating, and the luminescent bead actually provide a energy accepting surface.
  • the bead can absorb most of the donor emitted light, a simple radiative enery transfer can be applied, in which the energy transfer is a function of space angle and critical distance with 10 ⁇ m beads is in the range of micrometers.
  • the binding proteins e.g. agglutinin
  • a preferred arrangement is thus to use surface activated beads and use part of the reactive groups for coupling with acceptor molecules, or use acceptor-labelled binding surface (such as rhodamine labelled agglutinin) or to label coated protein afterwards with acceptors .
  • the preferred way to measure binding is to follow acceptor signal increase.
  • the acceptor signal is measured using a filter optimized for the donor used, having good transmission at the wavelength of acceptor, but more importantly, absolutely well blocked for each emission lines of the donor.
  • the filter should not leak any emission emanating form the main emission line of donor (such as 545 or 490 nm of Tb and 613-615 nm of Eu).
  • the energy transfer filter has to be situated at wavelength area, where there are no minor emission lines with the used donor.
  • Use of suitable delay avoid the interference derived from direct excitation of acceptor (the optimal delay depends on the length of excitation pulse used, but should be at least ten times longer) .
  • the decay of the energy transfer excited acceptor is a function of the decay of donor and the energy transfer efficiency.
  • the overall decay is not constant, but is a function of the analyte.
  • the decay time of energy transfer emission of acceptor is quite constant and equal to the decay time of donor. The delay and counting times for such measurement is not critical. For assays of higher efficiencies, the decay time decreases upon binding, and steeper response can be obtained keeping short delay time and reasonable short counting time.
  • the sample may have a signal decreasing effect.
  • the sample may, for example, absorb excitation light, emission light or cause other types of quenchings .
  • the interferences can be controlled by various methods, including (1) decay analysis (2) simultaneous photometric monitoring of sample absorption at the wavelengths of excitation and emission, (3) simultaneous measurement of both signals, donor and acceptor, and calculating their correlation and comparing to control with same amounts of donor and acceptor without binding reaction or (4) kinetic measurement during binding following the change of energy transfer or signals.
  • the analysis of decay time is an independent parameter not affected by color quenching of neither the excitation nor emission.
  • the decay change can be followed both for donor or for acceptor (decrease in decay when energy transfer increases).
  • a preferred way to quarantee nondisturbed analysis with all samples is to use suitable combination of all the above mentioned correction methods .
  • the energy transfer is registered by a time-resolved fluorometer using a predeterminated instrumental setting avoiding cross talk or donor emission to the channel used for acceptor emission measurement when there is no energy transfer.
  • the instrument automatically corrects any attenuation of excitation the sample may cause by following simultaneously the absorbances of the samples diluted into assay mixture and correcting the emission readings according to excitation or emission attenuation by sample absorption.
  • the measured acceptor signal can be normalized by recording also the donor emission which can be compared to zero calibrator, the lowering of signal without concomitant increase in acceptor luminescence being recorded and corrected.
  • the decay time of either donor or the acceptor can be registered and used as the measuring parameter.
  • the decay time of the donor or the acceptor can be utilized in correction of sample interferences .
  • a second type of assay where improved energy transfer assays can be applied are assays where dissociations, and not associations, are followed.
  • Such assays can be e.g. competitive immunoassays (or other specific binding assay) where antibody-antigen complex is preformed and the addition of analyte causes new equilibrium formations (ligand replacement assays).
  • Another group of such assay are the assays of cleaving enzymes, such as peptidases (e.g. HIV peptidases), proteases and other enzymes (e.g. nucleotide hydrolyzing enzymes, helicase, etc.).
  • peptidases e.g. HIV peptidases
  • proteases e.g. nucleotide hydrolyzing enzymes, helicase, etc.
  • the preferred technology is to follow the increased emission of the donor .
  • Preferred chelates for assays based on dissociation are to a great extend same as described above for association based assays.
  • Terbium is often a better choice, because it can be quenched with a variety of compounds, including metal ions, nitrogen compounds such as azide, nitride (Tanaka et al, J Photochem Photobiol 74; 15, 1993) or radicals (spin labels, such as Doxyl , Proxyl or Tempo and other N-0 compounds containing unpaired electron) (Matko et al, Biochemistry 31; 703, 1992).
  • Good Tb chelates suitable for the present invention are mentioned above .
  • a preferred acceptor for dissociation measuring assay is a good energy acceptor causing as efficient donor quenching as possible.
  • the acceptor can be luminescent, but does not have to be .
  • a preferred FRET acceptor has good acceptor properties (R 0 over 5 nm) , but does not have to be highly luminescent.
  • the good acceptor can be a respective compound made non-luminescent with heavy atom conjugations (such as erythrosin) or suitable other substituents (see. e.g. Khanna and Ullman, Anal Biochem 108; 156, 1980, Ullman and Khanna, Methods Enzymol 74; 28, 1981).
  • steric interference e.g.
  • acceptor has to be small, and small molecular quenchers, such as spin labels, are preferred.
  • Use of larger acceptors possibly requires indirect approach, i.e. use of small affinity label (small hapten, biotin) and separate step for quenching (addition of acceptor labelled anti-hapten of avidin), which may have to be done after the actual dissociation reaction (end point detection).
  • a preferred assay design for e.g. a peptidase is to use peptide substrate labelled at one end with a fluorescent terbium chelate and at the other end with free radical.
  • spin quenching and FRET dipole-dipole energy transfer depends on the actual distance between the labels in unhydrolyzed peptide. With small distances (below 2 nm) free radical (spin) is preferred. If the distance of the two probes would be more than 5 nm, a dipole-dipole energy transfer is preferred.
  • the energy donor Compound 6 was conjugated to anti- ⁇ hCG antibody (code F19-9C1, Wallac Oy, Turku, Finland) in the following way: anti- ⁇ hCG antibody (5mg/ml) was incubated with a 30-fold molar excess of Compound 6 in 50mM carbonate buffer pH 9.5 over night at +4 °C.
  • the labelled antibodies were separated from unreacted Compound 6 by gel filtration (Sepharose 6B with Sephadex G50 overlay, 0.5x70 cm, Pharmacia, Uppsala, Sweden) with Tris (50 mM Tris-HCl, pH 8 containing 0.9% NaCl) as eluetion buffer.
  • Tris 50 mM Tris-HCl, pH 8 containing 0.9% NaCl
  • the labelled antibody was analyzed and found to contain 4.7 molecules of Compound 6 per antibody. Labelled antibody was kept in Tris buffer, pH 7.4 containing 0.1% bovine serum albumin.
  • the energy acceptor TRITC (Molecular Probes Inc, Eugene, OR) was conjugated to anti- ⁇ hCG antibody (code M15294, Wallac Oy) in the following way: anti- ⁇ hCG antibody (5 mg/ml ) was incubated with a 15-fold molar excess of TRITC in 50 mM carbonate buffer pH 9.5 over night at +4 °C.
  • the labelled antibodies were separated from unreacted TRITC by gel filtration (Sepharose 6B with Sephadex G50 overlay, 0.5x70 cm, Pharmacia) with Tris (50 mM Tris-HCl, pH 8 containing 0.9% NaCl ) as eluetion buffer.
  • the labelled antibody was analyzed and found to contain 1,7 tetramethylrhodamine per antibody. Labelled antibody was kept in Tris buffer, pH 7.4 containing 0.1% bovine serum albumin .
  • Two antibodies (Wallac Oy) recognising different epitopes on PSA were labelled with Compound 1 and TRITC, respectively.
  • Antibody labelling were carried out as described in example 1 and 2.
  • 50 ⁇ l of PSA standard from the commercially available PSA assay kit DELFIA PSA
  • 50 ⁇ l of PSA standard was incubated together with 100 ng of Compound 1 (donor) labelled antibody and 100 ng of tetramethylrhodamine labelled antibody (acceptor) in 200 ⁇ l Tris buffer pH 7.4.
  • the assay mixtures were incubated for 30 min at room temperature under continous shaking.
  • the tetramethylrhodamine fluorescence from the formed complexes (sandwiches) was measured in the Wallac 1420 VICTOR time-resolved fluorometer (Excitation at 340 nm, emission at 572 nm +- 3 nm, delay time 50 ⁇ s, window time 100 ⁇ s, cycle time 1 ms ) .
  • the standard curve for the homogenous energy transfer assay is documented in Figure 4.
  • This two-site immunoassay was performed as described in Example 3. Instead of using tetramethylrhodamine-labelled antibody (acceptor), biotinylated antibody and tetramethylrhodamine-avidin (acceptor) was used. The tetramethylrhodamine-avidin (Molecular Probes) reacts and forms stable complexes with the biotinylated antibody.
  • the anti- ⁇ hCG antibody code M15294
  • the tetramethylrhodamine fluorescence from the formed complexes (sandwiches) was measured in the Wallac 1420 VICTOR time-resolved fluorometer (excitation at 340 nm, emission at 572 nm +- 3 nm, delay time 50 ⁇ s, window time 100 ⁇ s, cycle time 1 ms ) .
  • the standard curve for the homogenous energy transfer assay is documented in Figure 5.
  • Monoclonal anti-progesterone antibody (Wallac Oy) was labelled with Compound 2 according to Example 1.
  • Tris buffer was used in the incubations.
  • 50 ⁇ l standard or sample was incubated 100 ⁇ l of Compound 2 -labelled antibody (diluted 1/50000) and 100 ⁇ l of progesterone-biotin derivative and tetramethylrodamin-avidin (acceptor).
  • the biotinylated progesterone competes with progesterone from the standards or the sample for the binding sites on the labelled anti-progesterone antibody.
  • the reaction mixture was incubated for 1 hour at room temperature . After the incubation the fluorescence signal was measured from tetramethylrodamin-avidin bound to the anti-progesterone-antibody-progesterone-biotin complexes with a time-resolved fluorometer (Wallac 1420 VICTOR, excitation at 340 nm, emission at 572 nm, +- 3 nm, delay time 50 ⁇ s, window time 100 ⁇ s, cycle time 1 ms ) .
  • the measured signal is inversely related to the progesterone concentration in the sample.
  • IL-2 Purified carrier-free IL-2 (R&D Systems, Minneapolis, MN) (1 mg/ml) was incubated with a 10-fold molar excess of Compound 2 in 50mM carbonate buffer pH 9.2 over night at + 4 °C.
  • the labelled IL-2 was separated from unreacted chelate by gel filtration (Sephadex G50, 0.7x48 cm, Pharmacia) with Tris as elution buffer.
  • the labelled IL-2 was analyzed and found to contain 1.4 molecules of Compound 2 per IL-2 molecule.
  • a non-neutralizing antibody directed against the IL-2 receptor was labelled with tetramethylrhodamine isothiocyanate according to Example 2.
  • VICTOR excitation at 340 nm, emission at 572 nm +- 3 nm, delay time 50 ⁇ s, window time 100 ⁇ s , cycle time 1 ms ) .
  • casein Five milligrams of casein was dissolved in 0.5 mL of 0.1 M sodium carbonate pH 9.2. Fifty icroliters of 5.5 mM fluorescent Compound 6 in water was added to the casein solution and reaction was allowed to proceed overnight at 4 °C. The labelled protein was purified through Sephadex G-50 column using 0.9 % sodium chloride in aqueous solution as an eluent. The labelled casein was analyzed and found to contain one Compound 6 molecule per casein molecule. Two milligrams of Compound 6 -labelled casein in 1 mL was mixed with 100 ⁇ l of 20 mM tetramethylrhodamine isothiocyanate
  • TRITC TRITC dissolved in dimethylformamide . After adjusting pH by adding 120 ⁇ l of 1 M sodium carbonate, pH 9.5, reaction mixture was incubated at 4 °C overnight. The labelled protein was purified from unreacted TRITC using Sephadex G-50 column equilibrated and run with 50 mM Tris-HCl pH 8 containing 0.9% NaCl. Using the same protocol as for Compound 6 -labelled casein, unlabelled casein was also labelled with TRITC.
  • Casein labelled with Compound 6 and TRITC gave 28 000 cps, casein labelled with Compound 6 and PROXYL 54 000 cps and casein labelled with TRITC 869 cps.
  • the abovementioned proteins were measured using excitation at 340 nm, emission at 572 nm +- 3nm (suitable for TRITC), delay time 50 ⁇ s, window time 100 ⁇ s and cycle time 1 ms
  • Compound 6 -labelled casein gave 3952 cps, Compound 6- and TRITC-labelled casein 382 000 cps, Compound 6- and PROXYL-labelled casein 4097 cps and TRITC-labelled casein 747 cps.
  • Rhodamine-avidin Rh-Av
  • PE-Av phycoerythrin-avidin
  • the biotin moiety was coupled to the amino terminus of the peptide.
  • This peptide is a substrate for Abl protein tyrosine kinase purchased from New England Biolabs .
  • the assay was started by incubating 100 nM peptide solution with labelled avidin (concentration 10 ⁇ g/mL). Twenty microliters of peptide-avidin solution was pipetted to clear microtitration wells.
  • Rhodamine-avidin 2649 cps 702 000 cps
  • oligonucleotides were synthesized using Applied Biosystems DNA/RNA synthesizer:
  • oligonucleotides were synthesized and labelled using the chemistry and protocol published earlier (P. Dahlen et al . (1994) Bioconjugate Chem. 5, 268-272).
  • X denotes a modified deoxycytidine residue carrying an aliphatic primary amino group suitable for labelling with reagents containing, for example, isothiocyanate group.
  • Compound 6 used in this example is fluorescent.
  • the labelled probes are able to hybridize with the target oligonucleotide so that upon hybridization the fluorescent Compound 6 and tetramethylrhodamine are separated only by two nucleotides in the target oligonucleotide.
  • hybridization solution 0.6 M sodium chloride, 50 mM Tris-HCl pH 8, 0.1 mM EDTA, 0.1% sodium dodecylsulphate .
  • the probes were diluted in hybridization solution to give the final concentration of 10 nM each.
  • the target oligonucleotide was diluted also in hybridization buffer to give the following concentrations: 1 nM (in the assay 0.1 nM) , 5 nM (in the assay 0.5 nM) and 10 nM (in the assay 1 nM) .
  • Hybridization solution alone was used as a target for blank.
  • Anti- ⁇ hCG antibody (code M15294) was labelled with Compound 6 as described in Example 1. Fifty microliter of orange fluorescent beads (1.8x10 beads/ml) ( FluoroSpheres , F-8857 from Molecular Probes Inc.) were incubated with 50 ⁇ l Compound 6 -labelled antibody (60 ⁇ g/ l ) in Tris buffer (50 mM Tris-HCl, pH 7.4 containing 0.9% NaCl) for 2 hours. In the reaction mixture Compound 6 -labelled antibody is passively absorbed to the surface of the bead. The background was determined by incubating 50 ⁇ l of beads with 50 ⁇ l buffer and 50 ⁇ l of antibody solution with 50 ⁇ l of buffer.
  • the fluorescence from the acceptor molecules in the beads excited by energy transfered from Compound 6 was measured in the Wallac 1240 VICTOR time-resolved fluorometer. Fluorometer setting used were: excitation at 340 nm, emission at 572 nm +- 3nm, delay time 50 ⁇ s , window time 100 ⁇ s, cycle time 1 ms . Results:
  • Anti- ⁇ hCG antibody (code M15294) was labelled with Compound 9 as described in Example 1.
  • Fifty microliter of crimson fluorescent beads (1.8x10 beads/ml) (FluoroSpheres R ) , F-8855 from Molecular Probes Inc.) were incubated with 50 ⁇ l Compound 9 -labelled antibody (60 ⁇ g/ml ) in Tris buffer (50 mM Tris-HCl, pH 7.4 containing 0.9% NaCl) for 2 hours.
  • Tris buffer 50 mM Tris-HCl, pH 7.4 containing 0.9% NaCl
  • Compound 9 -labelled antibody is passively absorbed to the surface of the bead.
  • the background was determined by incubating 50 ⁇ l of beads with 50 ⁇ l buffer and 50 ⁇ l of antibody solution with 50 ⁇ l of buffer.
  • the fluorescence from the acceptor molecules in the beads excited by energy transfered from Compound 9 was measured in the Wallac 1240 VICTOR time-resolved fluorometer. Fluorometer setting used were: excitation at 340 nm, emission at 660 nm +- 1 nm, delay time 100 ⁇ s , window time 100 ⁇ s , cycle time 1 ms . Results:

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Optics & Photonics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Reproductive Health (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The invention relates to improvements of energy-transfer based homogeneous assays, which use time-resolved fluorometry in detection. The specific improvements relate to the type of lanthanide chelate labels used as energy donors, optimized energy acceptors for defined assays, the way energy transfer is measured using optimized filters and time windows, ways to correct all possible interferences derived from samples, use the assay for multi-component analysis and development of simplified assay protocols.

Description

HOMOGENOUS LUMINESCENCE ENERGY TRANSFER ASSAYS
FIELD OF THE INVENTION
The present invention relates to improvements of energy- transfer based homogeneous assays, which use time-resolved fluorometry in detection. The specific improvements relate to the type of lanthanide chelate labels used as energy donors, optimized energy acceptors for defined assays, the way energy transfer is measured using optimized filters and time windows, ways to correct all possible interferences derived from samples, use the assay for multi-component analysis and development of simplified assay protocols.
BACKGROUND OF THE INVENTION
The publications and other materials used herein to illuminate the background of the invention, and in particular, cases to provide additional details respecting the practice, are incorporated by reference.
A great variety of assays based on bioaffinity or enzymatically catalysed reactions have been developed to analyze biologically important compounds from various biological samples (such as serum, blood, plasma, saliva, urine, feces , seminal plasma, sweat, liquor, amniotic fluid, tissue homogenate, ascites, etc.), samples in environmental studies (waste water, soil samples) industrial processes (process solutions, products) and compound libraries (screening libraries which may comprise organic compounds, inorganic compounds, natural products, extracts of biological sources, biological proteins, peptides, or nucleotides, and so on). Some of these assays rely on specific bioaffinity recognition reactions, where generally natural biological binding components are used to form the specific binding assay (with biological binding components such as antibodies, natural hormone binding proteins, lectins , enzymes, receptors, DNA, RNA or PNA) or artificially produced binding compounds like genetically or chemically engineered antibodies, molded plastic imprint (molecular imprinting) and so on. Such assays generally rely on a label to quantitate the formed complexes after recognition and binding reaction and suitable separation (separations like precipitation and centrifugation, filtration, affinity collection to e.g. plastic surfaces such as coated assay tubes, slides of microbeads, solvent extraction, gel filtration or other chromatographic systems, and so on). The quantitation of the label in free or bound fraction enables the calculation of the analyte in the sample directly or indirectly, generally through use of a set of standards to which unknown samples are compared.
The separation and washing needed in most of these assays make them labor intensive, slow and difficult to automate. Furthermore the end point measurement does not allow gathering of kinetic information (associations/ dissociation rates). In cases of low affinity bindings, the affinity may be so low that no physical separation can be applied without destroying the binding (low affinity receptors). Particularly in areas, like screenings (high throughput screening) there is a constant demand for simpler assays, simplified protocols, which would make automation easier and increase the throughput. That can be accomplished with homogeneous or non-separations assays. Homogeneous biomedical assays are defined as assays taking place in one homogeneous phase. It means that no separate phases (such as solid phase catching reagents), and no separation is used prior to measurement. That requires a signal production system that responds to the binding assay in a way making its direct monitoring possible. Systems know prior art are e.g. fluorescence polarization assays applied for small molecular compounds, enzyme-monitored immunoassays (marketed by Syva ) , various fluorescence quenching or enhancing assays (for an review see e.g. Hemmila, Applications of Fluorescence in Immunoassays, Wiley, NY, 1991). Another category of simplified assay technologies are non-separation assays, which, similarly to homogenous assays, avoid separation and washing steps. A good example of such a technology is the scintillation proximity principle marketed by Amersham, which is based on short distance penetration of radiation particles in assay medium and solid scintillator coated with catching reagents (Udenfriend et al, (1985) Proc Natl Acad Sci, 82, 8672 and Anal Biochem, (1987) 161, 494).
Regardless of a great number of homogeneous assay designs published to day, there are no assays, where the versatility and sensitivity would match those of a good separation assay. The reason to that is manyfold relating to e.g. the different way homogeneous, versus heterogeneous, assay has to be optimized, the control of low affinity non-specific bindings, and the limitations of applicability of most of the existing homogenous assay techniques. In addition, the conventional homogeneous fluorometric assays are very vulnerable to background interferences derived from various components in the samples. Fluorescence polarizations assays are interfered by low affinity nonspecific bindings (e.g. probe binding to albumin) and autofluorescence of samples.
Time-resolved fluorometry (time resolution in time-domain at micro- or millisecond range) is a perfect measuring regime for homogeneous assays, because it can totally discriminate the background fluorescence derived from organic compounds when long enough delay times (time between pulsed excitation and starting of emission recording) are used (for a review see. e.g. Hemmila (1991); Gudgin Dickinson et al, (1995) J Photochem Photobiol 27, 3). In addition to separation based assays, also a number of homogeneous time resolved fluorometric assays have been described and patented (Mathis (1995) Clin Chem, 41, 1391; Selvin et al. (1994) Proc Natl Acad Sci, USA, 91, 10024) with their limitation and drawbacks . The aim of the present invention is i.a. to provide an improvement in time- resolved homogeneous assay principle based on specific energy transfer between a long life-time chelate-based donor probe and short life-time (or non-emitting) acceptor molecule.
Resonance Energy Transfer
The Fδrster type of nonradiative dipole-dipole energy transfer (Fδrster (1948) Ann Physik, 6, 55) takes place between two molecules in condition where their energies
(emission of donor with absorption of acceptor) overlap and they are at a distance less than 20 nm . The energy transfer requires a proper orientation of the oscillations of the molecules. The energy transfer efficiency ( ET) is given in the equation:
ΦET = 1/[1 + (r/R0)6]
where r is the distance between the donor and acceptor molecules and R0 is a distance parameter characteristic of the donor-acceptor pair and the medium between them.
Fluorescence resonance energy transfer (FRET) has been applied e.g. as an spectroscopic ruler in structural studies to measure distances within a macromolecule (Stryer and Haugland (1967) Proc Natl Acad Sci, USA, 58; 719). In addition to resonance energy transfer, there are also other energy transfer reactions, like simple radiative (where acceptor absorbs the light emitted by donor), collisional energy transfer, exchange (Dexter (1953) J Chem Physics, 21, 836) and exciton migration (in crystals). In addition, the donor emission can be quenched by numerous ways with a number of unrelated compounds having an deactivating effect on some of the donor's energy levels. Ullman was the first to describe application of Fδrster- type non-radiative energy transfer in bioanalytical assays based on antibody recognition reaction (Ullman, Scharzberg and Rubenstein (1967) J Biol Chem, 251; 4172) marketed as FETIA (fluorescence energy transfer immunoassay) by Syva Co. (US 3,996,345). Development of suitable energy donor- acceptor pairs are well described in their various reviews (Ullman and Khanna (1981) Methods Enzy ol, 74; 28; Khanna and Ullman (1980) Anal Biochem, 108, 156). FETIA primarily applies xanthene dyes and derivatives of fluorescein as donor and rhodamines as acceptors . A great number of alternative probe pairs have since been developed and applied in immunoassays (for a review see Hemmila 1991, chapter 8.3.4) including practically non-fluorescent derivatives of fluorescein, long life-time delayed fluorescence emittive eosin (Thakrar and Miller (1982) Anal Proc, 19, 329), long lifetime fluorescent pyrene (Morrison (1988) Anal Biochem, 174, 101) and non-e ittive charcoal. FRET has since got wide applications in basic research and in DNA hybridizations (see e.g. Morrison et al (1989) Anal Biochem, 183, 231; Parkhurst et al (1995) Biochemistry, 34, 285) and other assays were association, dissociation or distances are to be measured.
The use of temporal discrimination (time-resolution) to avoid the effect of direct excitation of acceptor molecule was described by Morrison (Morrison (1988) Anal Biochem, 174, 101) with organic donor-acceptor pairs of different decay times using pyrene as the long excited state donor, pulsed laser for excitation and phycoerythrin as the short decay-time acceptor (US 4,822,733). In addition to immunoassays, the time-resolved energy transfer principle is applied for homogeneous solution hybridization using fluorescein (Morrison et al (1989) Illrd International Symposium on Quantitative Luminescence Spectrometry in Biomedical Sciences, Ghent Belgium) as acceptor. The long excited state provides the advantage, that specific energy transfer can be followed using a delay time, during which the emission of directly excited acceptor is decayed off. The combination of different decay times exploited in time- resolved fluorometry will provide a clear advantage over FRET technologies employing conventional short decay probes .
Luminescent (fluorescent) lanthanides have long been used as tools for DNA and protein structural studies (See e.g. Brittain (1985) Bioinorganic Luminescence Spectroscopy, Schulman (ed), Molecular Luminescence Spectroscopy, Wiley, NY; Bϋnzli and Choppin (1989) Lanthanide Probes in Life, Chemical and Earth Sciences, Theory and Practice, Elsevier Science Publisher, Amsterdam), applied e.g. for RNA, ribosomes, DNA and chromatin, termolysin and transferrin, calmodulin, ATPase, nerve membranes, erythrocyte membrane proteins, phospholipids and liposomes and their fusions (for an review see Hemmila 1991). The energy transfer between lanthanides attached to different sites of a calcium binding protein, or DNA, have been used as spectroscopic ruler to measure the locations of ion-binding sites, e.g. with calmodulin using energy transfer between Eu and Nd (Horrocks and Tingey (1988) Biochemistry, 27, 413). Similarly FRET has been used in chelate studies by measuring energy transfer from Tb to Eu (Brittain (1978) Inorg Che , 17, 2762).
Lanthanides and their chelates are good candidates for time-resolved FRET experiments. Firstly, they have exceptionally long excited state lifetime (Weissman (1942) Chem Phys, 10, 214; Whan and Crosby (1962) Mol Spectrosc, 8, 315). The energy transfer takes place only between transitions that are electric dipole. The major transition in the highly fluorescent Eu chelates, (transition D0 - 7F2) at 612-620 n is electric dipole "forced" (Bϋnzli (1989) Lanthanide Probes in Life, Chemical and Earth Sciences. Theory and Practice, Bϋnzli and Choppin (ed) Elsevier Science, Publisher, Amsterdam) and can donate energy. The transition D0 - Fx producing emission at 590-595 nm is, however, magnetic dipole and can not transfer energy (Dexter, J Chem Phys 21? 836, 1953). In addition, lanthanide emission has isotropic dipolic moment, and hence the orientation factor becomes less ambiguous (Ando et al
(1992) Biochim Biophys Acta, 1102, 186).
Fluorescent lanthanide chelates have been used as energy donors already since 1978 by Stryer, Thomas and Meares. For example a Tb dipicolinate chelate reported to have the critical distance (R0) of 6.57 nm for rhodamine, 4.46 nm for eosin and 4.46 nm for NBD (Thomas et al (1978) Proc Natl Acad Sci, 75; 5746). Typically in an efficient energy transfer, the overall decay shortens, as shown in the above system, from 2.22 ms to 0.12 ms . Meares et al (1981, 1992) measured enzyme bound rifamycin using Tb-phenyl-EDTA as energy donor (Biochemistry 20; 610; Biochemistry 22; 6247). In addition to fluorescent compounds, also nonluminescent acceptors have been reported, such as Co (III) and Co (II) (Cronce and Horrocks (1992) Biochemistry 31, 7963). Eu and Tb chelates have also been tested as energy acceptors, Eu for coumarin derivative and Tb for salicylate derivative (Clark et al (1993) Anal Biochem 210, 1). The great number of available non-luminescent energy acceptors (quenchers) is an additional advantage for lanthanide chelates. They can be quenched by metallic ions, nitrite (Tanaka et al
(1993) J Photochem Photobiol A: Chem, 74, 15), other paramagnetic metallic ions and their chelates, free radicals (Matko et al (1992) Biochemistry 31, 703) and so on.
The use of lanthanides as fluorescent labels in various forms of bioaffinity assays are well documented in a great number of reviews and patents (see for example Hemmila 1991, Gudgin Dickson 1995). Examples of the early ideas about a 'workable' chelate label can be found e.g. in following patents (US 4,374,120; 4,432,907; 4,965,211; 4,341,957; 4,058,732 and 4,283,382). A heterogeneous assay system based on non-luminescent labelling chelates (US 4,808,541) and a dissociative fluorescence enhancement (US 4,565,790) has got the widest applications. That system, as well as system based on fluorogenic ligand and after-assay cationic saturation (EP-A 354847 and US 4,772,563), does not suit for homogeneous assays. There are, however, a great number of stable fluorescent chelates, described in patents and articles, which could be used in time-resolved FRET assays, such as mentioned in following US patents: 4,761,481; 5,032,677; 5,055,578; 5,106,957; 5,116,989; 4,761,481 4,801,722; 4,794,191; 4,637,988; 4,670,572; 4,837,169 and 4,859,777. The preferred chelate is composed of nona-dentate chelating ligand, such as terpyridine (EP-A 403593; US 5,324,825; US 5,202,423, US 5,316,909), terpyridine analogue with one or two five-membered rings (e.g. pyrazole, thiazole, triazine) (US Appl 08/548,174 and PCT/FI91/00373) . Very well suited chelates are also mentioned in following articles (Takalo et al (1994)
Bioconjugate Chem, 5, 278; Mukkala et al (1993) Helv Chim Acta, 76, 1361; Remuinnan et al (1993) J Chem Soc Perkin Trans, 2, 1099; Mukkala et al (1996) Helv Chim Acta, 79, 295; Takalo et al (1996) Helv Chim Acta, 79). Examples of other long decay time labels suitable for the present invention are the phosphorescent complexes of porphyrin derivatives with Pd and Pt (WO 94/10568) .
Use of long decay-time lanthanide chelates in various types of homogeneous binding assays are also described, based e.g. on mixed-ligand chelate (US 4,587,223), environmentally sensitive chelate ( EP 324323) and a chelate as enzyme substrate (EP 374221).
Since the development of the fluorescence resonance energy transfer based homogeneous assays in 1976, they have obtained wide applications in diagnostics, commercialized by Syva corporation (US 3,996,345). Use of lanthanide chelates as specific labels in time-resolving fluorometric systems was first described in 1970 's by Leif (Leif et al (1976) Automation of Uterine Cancer Cytology 1, GL Weid, GF Bahar and PH Bartels (ed) Tutorial of Cytology, Chicago IL) and Wieder (Wieder (1978) Proc. 6th Int. Conf . On Immunofluorescence and related staining techniques, W Knapp, K Holubar and G Wick (eds), North-Holland, Amsterdam; US 4,058,732, DE 2,628,158) followed by the development of working diagnostic systems in 1980 's (US 4,565,790). On the other hand, fluorescent lanthanides were used for fluorescence resonance energy transfer experiments already in 1978 by Stryer et al (Thomas et al (1978) Proc Natl Acad Sci, 75, 5746; Stryer et al, Annual Review of Biophysics and Bioengineering; Mullins LJ (ed) Annual Reviews, Inc; Palo Alto, CA, 1982, vol 11, p 203). Accordingly, their use as long excited state probes for FRET immunoassays is obvious, but still an object of patent applications. Wieder and Hale have obtained a patent on homogeneous time-resolved immunoassays based on various techniques, including energy transfer and quenchings (EP-A 272320 and WO 87/07955) and Stavrianopoulos (EP-A 242527, 1987) in an assay based on the use of Clq and FRET. Hoffman La Roche has patented a specific application using lumazine-t pe of chromophore as donor and a ruthenium chelate as acceptor for interactions between nucleic acids (EP 439036) and Cis Bio International applied for an assays based on Eu or Tb cryptates as donors for phycobiliproteins (WO 92/01225) .
The principle of a time-resolved homogeneous assay based on a specific energy transfer between a long-life time donor and a short life-time emitting acceptor molecule can be summarized as follows: The emission duration of a short excited state acceptor, excited during the excited lifetime of a long-decay time donor through the mechanism of energy transfer, is longer than the decay time of the directly excited acceptor. This fact permits the use of temporal discrimination (time-resolution) to avoid the luminescence from directly excited acceptor. In a homogenous assay based on energy transfer the long-lived donor is excited with a light pulse (A) (Figure 1). The luminescence emission of the energy-transfer excited acceptor is measured (D) after a suitable delay (C), to avoid interference derived from directly excited acceptor (B). The long-lived emission from the donor (DE) is avoided by measuring the emission of the energy-transfer excited acceptor (AE) at a wavelength where the donor emission is absent or negligible (Figure 2). Hence, in homogenous bioaffinity assay (receptor-ligand binding, hybridisation reaction, immunobinding, enzyme substrate binding etc.) the association or dissociation of donor-acceptor pairs can be followed by measuring the increase or decrease, respectively, in the signal from the energy-transfer excited acceptor.
OBJECTS AND SUMMARY OF THE INVENTION
An object of the present invention is to provide a luminescence energy transfer assay comprising a first group labelled with an energy donor and a second group labelled with an energy acceptor, wherein the acceptor is either a short excited state lifetime luminescent label or a non- luminescent label. The increase or decrease, respectively, in energy transfer from the donor label to the acceptor label resulting from shortening or lengthening, respectively, of the distance between said labels, is measured. According to the invention, the donor is a luminescent lanthanide chelate.
According to one aspect of the invention the assay is based on a reaction resulting in lengthening of the distance between the labelled donor and acceptor groups . According to this invention, the donor luminescent lanthanide chelate has a long excited state lifetime. According to another aspect of the invention the assay is based on a reaction resulting in either shortening or lengthening of the distance between the labelled donor and acceptor groups and the donor is a luminescent lanthanide chelate having a long excited state lifetime. According to this aspect of the invention the long excited state lifetime luminescent lanthanide chelate has one or more of the following properties:
- a high luminescence yield, - an excited state lifetime of 1 ms or more, and
- an emission distribution optimized for energy transfer.
According to yet another aspect of the invention, two or more analytes are simultaneously measured, wherein each analyte is measured by a specific donor-acceptor pair.
According to yet another aspect of the invention, the luminescent or non-luminescent label of the acceptor is attached to a solid carrier providing a large surface to which said second group is bound or can be bound via suitable covalent or non-covalent means.
According to yet another aspect of the invention, the acceptor is lipophilic compound anchored to a cell membrane or cell membrane fragment or the acceptor is made lipophilic by conjugating with a long chain hydrocarbon such as a fatty acid.
According to yet another aspect of the invention, the instrument used to measure energy transfer is able to follow multiple parameters simultaneously or consecutely, such as absorbances at the wavelenghts of excitation or emissions, luminescence of different durations, scattering and luminescence decay times, in order to monitor and correct any interferences the sample matrix may have to excitation, energy transfer or emissions. BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1 shows the luminescence versus time after donor excitation with a light pulse (A) of directly excited acceptor (B) and the luminescence emission of the energy- transfer excited acceptor (D) after a suitable delay (C).
Figure 2 shows the luminescence intensity versus emission wavelength of donor (DE) and acceptor (AE).
Figure 3 shows a standard curve for the homogenous energy transfer assay of BhCG (β-subunit of human chorionic gonadotropin) .
Figure 4 shows a standard curve for the homogenous energy transfer assay of PSA (prostate specific antigen).
Figure 5 shows a standard curve for the homogenous energy transfer assay of βhCG using indirect labelling.
Figure 6 shows a standard curve for the homogenous energy transfer assay of βhCG using indirect labelling and an acceptor different from that of Figure 5.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
The present invention relates to improvements of energy- transfer based homogeneous assays, which use time-resolved fluorometry in detection. The specific improvements relate to the type of lanthanide chelate labels used as energy donors, optimized energy acceptors for defined assays, the way energy transfer is measured using optimized filters and time windows, ways to correct all possible interferences derived from samples, use the assay for multi-component analysis and development of simplified assay protocols.
The terms "first group" and "second group" shall be understood to include any component such as bioaffinity recognition component (in reactions where the distance between the groups decreases, e.g. in bioaffinity reactions) or a part of a molecule or substrate (e.g. the distal ends of a peptide molecule the cleavage of which will separate the two labelled groups from each other).
The term "luminescence" shall cover fluorescense, phosphorescence, chemiluminescence, bioluminescence and electro-generated luminescence, photoluminescence, radioluminescence, sonoluminescence, thermoluminescence and triboluminescence .
A preferred arrangement in assays, where association is to be measured is to use luminescent, short decay time acceptor and long decay time lanthanide chelate based donor and follow the emission of acceptor molecule using a delay time in the time-resolved fluorometry to avoid the interference of acceptors direct luminescence (emanating from direct excitation of acceptor). It is desirable to construct the assay in a way that acceptor molecules are in excess (with time-resolved mode, their interference is negligible) and the association of binding reagents creates an increase in signal.
For such a system the preferred chelate label has to have high luminescence yield ( ExΦ >2000), long excited state lifetime (preferably over 1 ms ) and emission distribution optimized for energy transfer. The ligand field around the chelated ion has to be such that e.g. with Eu chelates over 70 % of emission is at D0 - F2 (at 610 - 620 nm range) and not at 590 nm range (compare e.g. emissions of Eu cryptate, WO 92/01225 and those of bis-iminoacetate derivatives of terpyridines, US 5,324,825; US 5,202,423 and US 5,316,909). In preferred chelates the useless magnetic dipole transition at 590 nm and emission around 700 nm are suppressed (Li and Selvin, J Amer Chem Soc 117; 8132, 1995). Particularly good chelates for the present application are Eu chelates formed with multichromogenic polycarboxylates, having high molar absorption coefficient (G), very long excited state lifetime and good quantum yield (Φ) (Takalo et al . Helv Chim Acta 79; 789, 1996). In addition to Eu, Tb is particularly promising energy donor, when its highly luminescent chelates are used. A preferred Tb chelate is composed of terpyridine derivatives containing the binding side at the iminodiacetate group (Mukkala et al, J Alloys Compounds 225; 507, 1995) or otherwise a binding arm well isolated from the light absorbing aromatic structure. Particularly good chelates for that applications are terpyridine derivatives where one or two pyridine rings are replaced with pyrazole (US 08/548,174) or triazole and thiazole rings (PCT/FI91/00373 ) . In addition to Eu and Tb, the use of S would give the possibility to make double- or triple-label homogeneous energy transfer assays. Sm has the advantage, that it can donate energy at a rather high wavelength, the major emission of a highly luminescent chelate being at 643 nm, giving the opportunity to continue with the wavelength scale up to near IR (a good collection of near-IR emitting fluors have become commercially available from different sources). A preferred stable chelate of Sm is composed of multiple forms of 1 , 3-diketones , such as described by Savitsky (Savitsky et al, SPIE 2388; 429, 1995). An alternative third choice (third label) is the phosphorescent Pt or Pd coproporphyrins emitting a long lifetime phosphorescence at 650-660 nm (WO 94/10568) .
A particularly preferred group of long excited state lifetime lanthanide chelates are Compounds 1 to 12 the structure of which is dislosed in Scheme 1 to 5. In the schemes λexc means excitation wavelength, τ decay time and G x Φ luminescence yield. The values given in the schemes are measured from the compound coupled to a protein. 98/15830
15
SCHEME 1
Figure imgf000017_0001
Figure imgf000017_0002
SCHEME 2
Figure imgf000018_0001
Figure imgf000018_0002
17
SCHEME 3
Figure imgf000019_0001
Figure imgf000019_0002
SCHEME 4
Figure imgf000020_0001
Figure imgf000020_0002
SCHEME 5
Figure imgf000021_0001
Figure imgf000021_0002
A preferred acceptor molecule for association assay is highly luminescent (with quantum yield as near unity (1) as possible) with high molar absorption coefficient (preferably over 100 000). The absorption of the acceptor has to overlap with the energy-donating emission of donor, i.e. at 611-620 nm for Eu, 545 nm for Tb, 643 nm for Sm. A preferred feature of the acceptor is its sharp emission at a wavelength where donor does not have any emission (such as 574-575 nm for Tb, 660-670 nm for Eu and around 675 for Sm) . The decay-time of the acceptor should be below lμs . In addition the acceptor has to be attached to binding partners, either directly or indirectly (e.g. via anti- binder antibody, lectin, avidin etc.), covalently or noncovalentl . As covalently conjugated probes, e.g. those of xanthene dyes (rhodamine, tetramethylrhodamine, Texas
Red TM (see e.g. Hemmila, 1991, Haugland, Handbook of Fluorescent Probes and Research Chemicals, Molecular Probes 1992-1994, Mayer and Neuenhofer, Angew Chem Int Ed Engl 33; 1044, 1994), some carbocyanines (Cy3.18) (Mujumbar et al, Bioconjugate Chem 4; 105, 1993, Southwick et al, Cytometry 11; 418,1990) and even some porphyrins (Camman, DE 4,216,696) can be used. B-phycoerythrin, due to its very high molar absorption coefficient (2,410,00 at 546 nm) and quantum yield (0.98) makes it very suitable for energy transfer assays, despite its large size (MW 240,000).
A good acceptor for Eu should have absorption maximum at 611-620 nm range. Good acceptor for that wavelength range can be found particularly from the group of IR emittive dyes (for reviews see Haugland Molecular Probes, Miller, Spectroscopy Europe 5; 34, 1993, Patonay and Antoine, Anal Chem 63; 332A, 1991, Southwick et al, Cytometry 11; 418, 1990, Mujumbar et al, Cytometry 10; 11, 1989 and Mujumbar et al, Bioconjugate Chem 4; 105, 1993, Papkovsky, Appl Fluorescence Technol III; 16, 1991, Schindele and Renzoni, J Clin Immunoassay 13; 182, 1993). These types of compounds include phthalocyanines , porphyrins, cyanine dyes (Cy-5, Cy5,18, Cy5,29) (Selvin et al, J Amer Chen Soc 116; 6029, 1994, Mujumbar et al, Bioconjugate Chem 4; 105, 1993), conjugated xanthenes (rhodamine 800) (Imasaka et al, Anal Chem 61; 2285, 1989), squarates (Chang, EP176,252), methylene blue, Nile blue and oxazines (Imasaka et al, Anal Chem 61; 2285, 1989), indocyanine green (Imasaka et al, Anal Chem 62; 363A, 990). Some of the phycobiliproteins are good candidates also for Eu acceptors, particularly A- PC, C-PC and R-PC . A preferred energy acceptor for Sm or for coproporphyrins are the IR emittive dyes (see reviews mentioned above).
A preferred way to ascertain small distances between donor probe labelled ligand or binding reagent and acceptor probe labelled binding reagent is to use activated probes coupled directly to binding reagent (e.g. acceptor labelled receptor protein, antibody or other binding protein). An alternative way is to use indirect labelling, using e.g. anti-binder (such as anti-receptor) antibodies labelled with the acceptor, use of biotinylated binder and acceptor labelled ( strept )avidin or to employ other bioaffinity reactions to bring acceptor molecules in the vicinity of actual binding site, where the donor-labelled component either directly or indirectly will be bound.
A preferred way with impure, membrane-bound receptors is to use lipophilic membrane probes and stain all the membranes near or around the receptor with acceptor molecules . Suitable probes attached to long aliphatic hydrocarbon chain, such as e.g. oxacarbocyanine (Molecular Probes) are suitable for such staining.
A further alternative, which would avoid separate labelling of binding components for each particular assay, is to use solid carriers (polymers, ceramics or glass or the like) such as universal catching surfaces containing high concentration of acceptor molecules . Suitable solid carriers can be e.g. beads or particles with a diameter up to 1500 μm or any solid surface. Microbeads labelled with a wide variety of luminescent probes are available from different sources. A preferred probe used in the carrier is a hydrophobic compound, having negligible solubility to water to avoid leakage. A variety of probes suitable for such labelling can be found amongst scintillator and laser dyes . With highly luminescent beads the great number of acceptor molecules may compensate the long distance after bead coating, and the luminescent bead actually provide a energy accepting surface. When the bead can absorb most of the donor emitted light, a simple radiative enery transfer can be applied, in which the energy transfer is a function of space angle and critical distance with 10 μm beads is in the range of micrometers. For FRET-based assay, however, when the plastic is first coated with the binding proteins (e.g. agglutinin) to immobilize membrane receptors, may result in inefficient energy transfer due to long distances. A preferred arrangement is thus to use surface activated beads and use part of the reactive groups for coupling with acceptor molecules, or use acceptor-labelled binding surface (such as rhodamine labelled agglutinin) or to label coated protein afterwards with acceptors .
In homogeneous assay of a association reaction
( immunobinding , receptor-ligand binding, hybridizations reaction, enzyme-substrate binding etc.) the preferred way to measure binding is to follow acceptor signal increase. The acceptor signal is measured using a filter optimized for the donor used, having good transmission at the wavelength of acceptor, but more importantly, absolutely well blocked for each emission lines of the donor. The filter should not leak any emission emanating form the main emission line of donor (such as 545 or 490 nm of Tb and 613-615 nm of Eu). In addition the energy transfer filter has to be situated at wavelength area, where there are no minor emission lines with the used donor. Use of suitable delay avoid the interference derived from direct excitation of acceptor (the optimal delay depends on the length of excitation pulse used, but should be at least ten times longer) .
The decay of the energy transfer excited acceptor is a function of the decay of donor and the energy transfer efficiency. Thus, during the assay (such as competitive binding assay or non-competitive assay) the overall decay is not constant, but is a function of the analyte. In association assays where specific binding is low and energy transfer efficiency less than 1 %, the decay time of energy transfer emission of acceptor is quite constant and equal to the decay time of donor. The delay and counting times for such measurement is not critical. For assays of higher efficiencies, the decay time decreases upon binding, and steeper response can be obtained keeping short delay time and reasonable short counting time. On the other hand, if donor emission is followed, steeper response is obtained using long delay time, because when energy transfer occurs, the total donor emission both decreases and its decay time shortens. For optimized results in any assay, it is advisable to optimize counting windows according to assay type, specific binding percentages and energy transfer efficiencies .
In screening of various compounds or samples, the sample may have a signal decreasing effect. The sample may, for example, absorb excitation light, emission light or cause other types of quenchings . In a multi-label counter, such as Wallac 1420 VICTOR, the interferences can be controlled by various methods, including (1) decay analysis (2) simultaneous photometric monitoring of sample absorption at the wavelengths of excitation and emission, (3) simultaneous measurement of both signals, donor and acceptor, and calculating their correlation and comparing to control with same amounts of donor and acceptor without binding reaction or (4) kinetic measurement during binding following the change of energy transfer or signals. With binding assays of high efficiency, the analysis of decay time is an independent parameter not affected by color quenching of neither the excitation nor emission. The decay change can be followed both for donor or for acceptor (decrease in decay when energy transfer increases). A preferred way to quarantee nondisturbed analysis with all samples is to use suitable combination of all the above mentioned correction methods .
According to a preferred embodiment, the energy transfer is registered by a time-resolved fluorometer using a predeterminated instrumental setting avoiding cross talk or donor emission to the channel used for acceptor emission measurement when there is no energy transfer.
Preferably, the instrument automatically corrects any attenuation of excitation the sample may cause by following simultaneously the absorbances of the samples diluted into assay mixture and correcting the emission readings according to excitation or emission attenuation by sample absorption.
The measured acceptor signal can be normalized by recording also the donor emission which can be compared to zero calibrator, the lowering of signal without concomitant increase in acceptor luminescence being recorded and corrected.
The decay time of either donor or the acceptor can be registered and used as the measuring parameter.
The decay time of the donor or the acceptor can be utilized in correction of sample interferences .
A second type of assay where improved energy transfer assays can be applied, are assays where dissociations, and not associations, are followed. Such assays can be e.g. competitive immunoassays (or other specific binding assay) where antibody-antigen complex is preformed and the addition of analyte causes new equilibrium formations (ligand replacement assays). Another group of such assay are the assays of cleaving enzymes, such as peptidases (e.g. HIV peptidases), proteases and other enzymes (e.g. nucleotide hydrolyzing enzymes, helicase, etc.). In homogeneous measurement of dissociation, the preferred technology is to follow the increased emission of the donor .
Preferred chelates for assays based on dissociation are to a great extend same as described above for association based assays. Terbium, however, is often a better choice, because it can be quenched with a variety of compounds, including metal ions, nitrogen compounds such as azide, nitride (Tanaka et al, J Photochem Photobiol 74; 15, 1993) or radicals (spin labels, such as Doxyl , Proxyl or Tempo and other N-0 compounds containing unpaired electron) (Matko et al, Biochemistry 31; 703, 1992). Good Tb chelates suitable for the present invention are mentioned above .
A preferred acceptor for dissociation measuring assay is a good energy acceptor causing as efficient donor quenching as possible. The acceptor can be luminescent, but does not have to be . A preferred FRET acceptor has good acceptor properties (R0 over 5 nm) , but does not have to be highly luminescent. In addition to luminescent compounds mentioned above, the good acceptor can be a respective compound made non-luminescent with heavy atom conjugations (such as erythrosin) or suitable other substituents (see. e.g. Khanna and Ullman, Anal Biochem 108; 156, 1980, Ullman and Khanna, Methods Enzymol 74; 28, 1981). To avoid steric interference (e.g. with HIV peptides labelled both with donor and with acceptor), the acceptor has to be small, and small molecular quenchers, such as spin labels, are preferred. Use of larger acceptors possibly requires indirect approach, i.e. use of small affinity label (small hapten, biotin) and separate step for quenching (addition of acceptor labelled anti-hapten of avidin), which may have to be done after the actual dissociation reaction (end point detection). A preferred assay design for e.g. a peptidase is to use peptide substrate labelled at one end with a fluorescent terbium chelate and at the other end with free radical. The choice between spin quenching and FRET dipole-dipole energy transfer depends on the actual distance between the labels in unhydrolyzed peptide. With small distances (below 2 nm) free radical (spin) is preferred. If the distance of the two probes would be more than 5 nm, a dipole-dipole energy transfer is preferred.
When designed to be quenched in associated form (such as quenched substrate), the donor luminescence, and its decay time is increased upon dissociation. So the preferred delay time in measurement is long, to avoid detecting of possible remaining luminescence of quenched donor. These assays, similar to association assays, are sometimes prone to sample interferences (e.g. color quenchings ) , and the problems can be solved similarly as described above.
EXAMPLES
The invention is further demonstrated by the following non- limiting examples .
Example 1
Labelling of anti-βhCG (human chorionic gonadotropin ) antibody (code F19-9C1) with the fluorescent Tb chelate Compound 6
The energy donor Compound 6 was conjugated to anti-βhCG antibody (code F19-9C1, Wallac Oy, Turku, Finland) in the following way: anti-βhCG antibody (5mg/ml) was incubated with a 30-fold molar excess of Compound 6 in 50mM carbonate buffer pH 9.5 over night at +4 °C. The labelled antibodies were separated from unreacted Compound 6 by gel filtration (Sepharose 6B with Sephadex G50 overlay, 0.5x70 cm, Pharmacia, Uppsala, Sweden) with Tris (50 mM Tris-HCl, pH 8 containing 0.9% NaCl) as eluetion buffer. The labelled antibody was analyzed and found to contain 4.7 molecules of Compound 6 per antibody. Labelled antibody was kept in Tris buffer, pH 7.4 containing 0.1% bovine serum albumin.
Example 2
Labelling of anti-βhCG (code M15294) antibody with tetramethylrhodamine isothiocyanate (TRITC)
The energy acceptor TRITC (Molecular Probes Inc, Eugene, OR) was conjugated to anti-βhCG antibody (code M15294, Wallac Oy) in the following way: anti-βhCG antibody (5 mg/ml ) was incubated with a 15-fold molar excess of TRITC in 50 mM carbonate buffer pH 9.5 over night at +4 °C. The labelled antibodies were separated from unreacted TRITC by gel filtration (Sepharose 6B with Sephadex G50 overlay, 0.5x70 cm, Pharmacia) with Tris (50 mM Tris-HCl, pH 8 containing 0.9% NaCl ) as eluetion buffer. The labelled antibody was analyzed and found to contain 1,7 tetramethylrhodamine per antibody. Labelled antibody was kept in Tris buffer, pH 7.4 containing 0.1% bovine serum albumin .
Example 3
Homogenous energy transfer assay of βhCG
In this two-site immunoassay, 50 μl of βhCG standard in the wells of 96-well plates was incubated with 100 ng of Compound 6 -labelled antibody (donor) and 100 ng of tetramethylrhodamine labelled antibody (acceptor) in 200 μl Tris buffer (50 mM Tris-HCl, pH 7.4, containing 0.9 % NaCl). The two anti-βhCG antibodies used are directed against different specific antigenic sites on the βhCG subunit. The βhCG standards were from a commercially available kit for the measurement of free βhCG in serum (Wallac Oy) . The reaction mixtures were incubated for 30 min at room temperature on a 96-well plate shaker. The tetramethylrhodamine fluorescence from the formed complexes was measured in a time-resolved fluorometer (excitation at 340 nm, emission at 572 nm +- 3 nm, delay time 50 μs, window time 100 μs, cycle time 1 ms ) , model 1420 VICTOR (Wallac Oy) A standard curve for the energy transfer assay of βhCG is presented in Figure 3.
Example 4
Homogenous energy transfer assay of PSA (prostate specific antigen )
Two antibodies (Wallac Oy) recognising different epitopes on PSA were labelled with Compound 1 and TRITC, respectively. Antibody labelling were carried out as described in example 1 and 2. In this two-site immunoassay, 50 μl of PSA standard (from the commercially available PSA assay kit DELFIA PSA) was incubated together with 100 ng of Compound 1 (donor) labelled antibody and 100 ng of tetramethylrhodamine labelled antibody (acceptor) in 200 μl Tris buffer pH 7.4. The assay mixtures were incubated for 30 min at room temperature under continous shaking. The tetramethylrhodamine fluorescence from the formed complexes (sandwiches) was measured in the Wallac 1420 VICTOR time-resolved fluorometer (Excitation at 340 nm, emission at 572 nm +- 3 nm, delay time 50 μs, window time 100 μs, cycle time 1 ms ) . The standard curve for the homogenous energy transfer assay is documented in Figure 4.
Example 5
Homogenous energy transfer assay of βhCG with tetramethyl- rhoda ine-avidin as acceptor
This two-site immunoassay was performed as described in Example 3. Instead of using tetramethylrhodamine-labelled antibody (acceptor), biotinylated antibody and tetramethylrhodamine-avidin (acceptor) was used. The tetramethylrhodamine-avidin (Molecular Probes) reacts and forms stable complexes with the biotinylated antibody. The anti-βhCG antibody (code M15294) was biotinylated according to the instructions from the biotin reagent supplier (Biotinylating Reagent 732494, Boehringer Mannheim, Mannheim, Germany) . The tetramethylrhodamine fluorescence from the formed complexes (sandwiches) was measured in the Wallac 1420 VICTOR time-resolved fluorometer (excitation at 340 nm, emission at 572 nm +- 3 nm, delay time 50 μs, window time 100 μs, cycle time 1 ms ) . The standard curve for the homogenous energy transfer assay is documented in Figure 5.
Example 6
Homogenous energy transfer assay of βhCG with R-phycoerythrin-avidin as acceptor
In this experiment R-phycoerythrin-avidin (Molecular Probes, Eugene, OR, USA) was used instead of tetramethylrhodamine-avidin, otherwise the experiment was performed as in Example 5. The R-phycoerythrin fluorescence from the formed complexes (sandwiches) was measured in the Wallac 1240 VICTOR time-resolved fluorometer (Excitation at 340 nm, emission at 572 nm +-3 nm, delay time 50 μs, window time 100 μs, cycle time 1 ms ) . The standard curve for the homogenous energy transfer assay is documented in Figure 6.
Example 7
Homogenous energy transfer assay of progesterone
Monoclonal anti-progesterone antibody (Wallac Oy) was labelled with Compound 2 according to Example 1. Progesterone-biotin derivative (Wallac Oy) was used at a concentration of 5/Kaff (Kaff = affinity constant of the progesterone antibody used) and about 2 times more tetramethylrodamin-avidin (from Molecular Probes, Inc, OR) was used. Tris buffer was used in the incubations. In this competitive immunonassay 50 μl standard or sample, was incubated 100 μl of Compound 2 -labelled antibody (diluted 1/50000) and 100 μl of progesterone-biotin derivative and tetramethylrodamin-avidin (acceptor). The biotinylated progesterone competes with progesterone from the standards or the sample for the binding sites on the labelled anti-progesterone antibody. The reaction mixture was incubated for 1 hour at room temperature . After the incubation the fluorescence signal was measured from tetramethylrodamin-avidin bound to the anti-progesterone-antibody-progesterone-biotin complexes with a time-resolved fluorometer (Wallac 1420 VICTOR, excitation at 340 nm, emission at 572 nm, +- 3 nm, delay time 50 μs, window time 100 μs, cycle time 1 ms ) . The measured signal is inversely related to the progesterone concentration in the sample.
Example 8
Homogenous energy transfer receptor assay of IL-2
Purified carrier-free IL-2 (R&D Systems, Minneapolis, MN) (1 mg/ml) was incubated with a 10-fold molar excess of Compound 2 in 50mM carbonate buffer pH 9.2 over night at + 4 °C. The labelled IL-2 was separated from unreacted chelate by gel filtration (Sephadex G50, 0.7x48 cm, Pharmacia) with Tris as elution buffer. The labelled IL-2 was analyzed and found to contain 1.4 molecules of Compound 2 per IL-2 molecule. A non-neutralizing antibody directed against the IL-2 receptor was labelled with tetramethylrhodamine isothiocyanate according to Example 2. In the homogenous receptor assay increasing concentrations of unlabelled IL-2 was co-incubated with constant quantities of Compound 2 -labelled IL-2 (donor), IL-2α receptor and the tetramethylrhodamine labelled antibody (acceptor). Tris buffer was used in this incubation. A displacement curve was constructed by measuring the fluorescence signal from the formed antibody-receptor-IL-2 complexes in a time-resolved fluorometer (Wallac 1420
VICTOR, excitation at 340 nm, emission at 572 nm +- 3 nm, delay time 50 μs, window time 100 μs , cycle time 1 ms ) .
Example 9
Double labelling of casein with a Compound 6 and terame hylrhodamine
Five milligrams of casein was dissolved in 0.5 mL of 0.1 M sodium carbonate pH 9.2. Fifty icroliters of 5.5 mM fluorescent Compound 6 in water was added to the casein solution and reaction was allowed to proceed overnight at 4 °C. The labelled protein was purified through Sephadex G-50 column using 0.9 % sodium chloride in aqueous solution as an eluent. The labelled casein was analyzed and found to contain one Compound 6 molecule per casein molecule. Two milligrams of Compound 6 -labelled casein in 1 mL was mixed with 100 μl of 20 mM tetramethylrhodamine isothiocyanate
(TRITC) dissolved in dimethylformamide . After adjusting pH by adding 120 μl of 1 M sodium carbonate, pH 9.5, reaction mixture was incubated at 4 °C overnight. The labelled protein was purified from unreacted TRITC using Sephadex G-50 column equilibrated and run with 50 mM Tris-HCl pH 8 containing 0.9% NaCl. Using the same protocol as for Compound 6 -labelled casein, unlabelled casein was also labelled with TRITC.
Example 10
Labelling of Compound 6 -labelled casein with a spin label.
Two milligrams of Compound 6 -labelled casein (Example 9) in 1 mL 0.9% NaCl was mixed with 110 μl of 1 M sodium carbonate pH 9.5 and 13 μl of 160 mM
3- ( 2- ( 2-Isothiocyanatoethoxy)-ethylcarbamoyl ) -PROXYL (Aldrich) was added. After overnight reaction at 4 °C the double labelled protein was purified using Sephadex G-50 column.
Example 11
Fluorometric properties of double-labelled caseins
The double-labelled proteins from Examples 9 and 10 together with Compound 6 casein (Example 9) were analyzed in a multilabel reader (VICTOR, Wallac Oy) . Labelled caseins were diluted in 50 mM Tris-HCl pH 7.8 to a concentration of 0.2 μg/mL. Using the protocol for terbium measurement (excitation 340 nm, emission 545 nm, delay time 0.5 ms , window time 1.4 ms , cycle time 2 ms ) Compound 6- labelled casein gave 743 000 counts per second (cps).
Casein labelled with Compound 6 and TRITC gave 28 000 cps, casein labelled with Compound 6 and PROXYL 54 000 cps and casein labelled with TRITC 869 cps. When the abovementioned proteins were measured using excitation at 340 nm, emission at 572 nm +- 3nm (suitable for TRITC), delay time 50 μs, window time 100 μs and cycle time 1 ms , Compound 6 -labelled casein gave 3952 cps, Compound 6- and TRITC-labelled casein 382 000 cps, Compound 6- and PROXYL-labelled casein 4097 cps and TRITC-labelled casein 747 cps. These results show that labelling of Compound 6- labelled casein with TRITC or PROXYL efficiently quenched Compound 6 -fluorescence. In the case of Compound 6- and TRITC-labelled casein quenching of Compound 6 -fluorescence is due to energy transfer between Compound 6 -chelate and rhodamine which can be seen in fluorescence signal using an emission filter suitable for rhodamine and time-resolved mode. Example 12
Protease assay using double-labelled caseins
Compound 6 -labelled casein, Compound 6- and TRITC-labelled casein and Compound 6- and PROXYL-labelled casein were diluted in 10 mM Tris-HCl pH 7.6 to a concentration of 50 ng/mL. 180 μl of each diluted protein was pipetted in clear microtitration wells (NUNC Maxisorp) . Fluorescence was measured using the protocol for terbium measurement. Following results were obtained: Compound 6 -casein 179 000 cps, Compound 6 -TRITC-casein 7860 cps and Compound 6
-PROXYL-casein 14680 cps. Then 100 ng of trypsin in 20 μl of 10 mM Tris-HCl pH 7.6 was added to each well. After incubating for 1 hour at room temperature Compound 6 -fluorescence was measured: Compound 6 -casein 163 000 cps, Compound 6 -TRITC-casein 137 000 cps and Compound 6 -PROXYL -casein 67400 cps. In case of double-labelled caseins there was up to 17-fold increase in Compound 6 -fluorescence upon degradation with a protease.
Example 13
Homogeneous energy transfer assay for measurement of a protein kinase activity
Antibody against phosphorylated tyrosine (clone PY20) was labelled with Compound 4. Incorporation of 3 chelates per antibody molecule was obtained. Rhodamine-avidin (Rh-Av) and phycoerythrin-avidin (PE-Av) were purchased from Vector Laboratories. As a substrate we used a peptide with a following amino acid sequence:
Biotin-Glu-Ala-Ile-Tyr-Ala-Ala-Pro-Phe-Ala-Lys-Lys-Lys . The biotin moiety was coupled to the amino terminus of the peptide. This peptide is a substrate for Abl protein tyrosine kinase purchased from New England Biolabs . The assay was started by incubating 100 nM peptide solution with labelled avidin (concentration 10 μg/mL). Twenty microliters of peptide-avidin solution was pipetted to clear microtitration wells. Next 75 μL of Abl protein tyrosine kinase assay buffer (New England Biolabs; 50 mM Tris-HCl pH 7.5, 10 mM MgCl2, 0.1 mM Na2EDTA, 1 mM dithiothreitol, 0.015% Brij 35) containing 25 μM ATP and 250 μg/mL Compound 3 -labelled anti-phosphotyrosine was added to each well. Then either 5 μL of kinase assay buffer (blank) or 5 μL of Abl protein tyrosine kinase (1 unit) diluted in assay buffer was added. Measurement was performed in VICTOR reader using time-resolved mode
(excitation at 340 nm, emission at 572 nm +- 3 nm, delay time 50 μs, window time 100 μs, cycle time 1 ms ) to measure signal from rhodamine or phycoerythrin excited by energy transfer from Compound 4. After 30 minutes following results were obtained:
Labelled avidin Blank Signal with enzyme
Rhodamine-avidin 2649 cps 702 000 cps
Phycoerythrin-avidin 2460 cps 974 000 cps
These results show that kinase activity can be detected using the described assay format based on energy transfer between Compound 4 and rhodamine or phycoerythrin .
Example 14
Homogeneous energy transfer DNA hybridization assay
The following oligonucleotides were synthesized using Applied Biosystems DNA/RNA synthesizer:
Target oligonucleotide 5 ' -ACG GTT CTA GCG TTG CAC TAC GGC
TGC AAC TAG CAG TCC-3'
Compound 6 -labelled oligonucleotide 5 ' -Compound 3-X-GTG
CAA CGC TAG AAC-3' Tetramethylrhodamine-labelled oligonucleotide 5 ' -TGC TAG
TTG CAG CCG-X-TRITC-3'
Compound 6- and TRITC-labelled oligonucleotides were synthesized and labelled using the chemistry and protocol published earlier (P. Dahlen et al . (1994) Bioconjugate Chem. 5, 268-272). X denotes a modified deoxycytidine residue carrying an aliphatic primary amino group suitable for labelling with reagents containing, for example, isothiocyanate group. Compound 6 used in this example is fluorescent. The labelled probes are able to hybridize with the target oligonucleotide so that upon hybridization the fluorescent Compound 6 and tetramethylrhodamine are separated only by two nucleotides in the target oligonucleotide. In the assays following hybridization solution was used: 0.6 M sodium chloride, 50 mM Tris-HCl pH 8, 0.1 mM EDTA, 0.1% sodium dodecylsulphate . The probes were diluted in hybridization solution to give the final concentration of 10 nM each. The target oligonucleotide was diluted also in hybridization buffer to give the following concentrations: 1 nM (in the assay 0.1 nM) , 5 nM (in the assay 0.5 nM) and 10 nM (in the assay 1 nM) . Hybridization solution alone was used as a target for blank. Twenty microliters of target oligonucleotide dilutions and blank was pipetted to clear microtitration wells. The assay was performed using two replicates. Then 180 μl of hybridization solution containing the labelled probes was added to each well. Then the plate was covered with adhesive tape and placed in an incubator set to 37 °C. After incubation for 30 minutes the plate was measured using the time-resolved mode (excitation at 340 nm, emission at 572 nm +- 3 nm, delay time 50 μs, window time 100 μs, cycle time 1 ms ) . Following results were obtained:
Blank 2331 cps
0.1 nM target 7170 cps
0.5 nM target 26980 cps
1 nM target 46300 cps
These results show that this homogeneous assay works well and the energy transfer between the Compound 6 and rhodamine is efficient when the two probes hybridize to the same target molecule.
Example 15
Energy transfer assay using beads containing acceptor molecules
Anti-βhCG antibody (code M15294) was labelled with Compound 6 as described in Example 1. Fifty microliter of orange fluorescent beads (1.8x10 beads/ml) ( FluoroSpheres , F-8857 from Molecular Probes Inc.) were incubated with 50 μl Compound 6 -labelled antibody (60 μg/ l ) in Tris buffer (50 mM Tris-HCl, pH 7.4 containing 0.9% NaCl) for 2 hours. In the reaction mixture Compound 6 -labelled antibody is passively absorbed to the surface of the bead. The background was determined by incubating 50 μl of beads with 50 μl buffer and 50 μl of antibody solution with 50 μl of buffer. The fluorescence from the acceptor molecules in the beads excited by energy transfered from Compound 6 was measured in the Wallac 1240 VICTOR time-resolved fluorometer. Fluorometer setting used were: excitation at 340 nm, emission at 572 nm +- 3nm, delay time 50 μs , window time 100 μs, cycle time 1 ms . Results:
Fluorescence lOOOxcps
50 μl beads + 50 μl Compound 6 -labelled antibody 5543
50 μl beads + 50 μl buffer 161 50 μl Compound 6 -labelled antibody + 50 μl buffer 158
Example 16
Energy transfer assay using beads containing acceptor molecules
Anti-βhCG antibody (code M15294) was labelled with Compound 9 as described in Example 1. Fifty microliter of crimson fluorescent beads (1.8x10 beads/ml) (FluoroSpheresR) , F-8855 from Molecular Probes Inc.) were incubated with 50 μl Compound 9 -labelled antibody (60 μg/ml ) in Tris buffer (50 mM Tris-HCl, pH 7.4 containing 0.9% NaCl) for 2 hours. In the reaction mixture Compound 9 -labelled antibody is passively absorbed to the surface of the bead. The background was determined by incubating 50 μl of beads with 50 μl buffer and 50 μl of antibody solution with 50 μl of buffer. The fluorescence from the acceptor molecules in the beads excited by energy transfered from Compound 9 was measured in the Wallac 1240 VICTOR time-resolved fluorometer. Fluorometer setting used were: excitation at 340 nm, emission at 660 nm +- 1 nm, delay time 100 μs , window time 100 μs , cycle time 1 ms . Results:
Fluorescence lOOOxcps
50 μl beads + 50 μl Compound 9 -labelled antibody 1398 50 μl beads + 50 μl buffer 8
50 μl Compound 9 -labelled antibody + 50 μl buffer 102
It will be appreciated that the methods of the present invention can be incorporated in the form of a variety of embodiments, only a few of which are disclosed herein. It will be apparent to the artisan that other embodiments exist and do not depart from the spirit of the invention.
Thus, the described embodiments are illustrative and should not be construed as restrictive.

Claims

1. A luminescence energy transfer assay comprising a first group labelled with an energy donor and a second group labelled with an energy acceptor, wherein
- the donor is a long excited state lifetime luminescent lanthanide chelate and the acceptor is either a short excited state lifetime luminescent label or a non- luminescent label, and
- and the increase or decrease, respectively, in energy transfer from the donor label to the acceptor label resulting from shortening or lengthening, respectively, of the distance between said labels, is measured characterized in that the long excited state lifetime luminescent lanthanide chelate has one or more of the following properties: - a high luminescence yield,
- an excited state lifetime of 1 ms or more, and
- an emission distribution optimized for energy transfer.
2. A luminescence energy transfer assay comprising a first group labelled with an energy donor and a second group labelled with an energy acceptor, wherein
- the acceptor is either a short excited state lifetime luminescent label or a non-luminescent label, and
- and the decrease in energy transfer from the donor label to the acceptor label resulting from lengthening of the distance between said labels, is measured characterized in that the donor is a long excited state lifetime luminescent lanthanide chelate.
3. A luminescence energy transfer assay comprising a first group labelled with an energy donor and a second group labelled with an energy acceptor, wherein
- the acceptor is either a short excited state lifetime luminescent label or a non-luminescent label, and
- and the increase or decrease, respectively, in energy transfer from the donor label to the acceptor label resulting from shortening or lengthening, respectively, of the distance between said labels, is measured characterized in that the donor is a luminescent lanthanide chelate, and
- two or more analytes are simultaneously measured, wherein each analyte is measured by a specific donor-acceptor pair and the donor and acceptor are selected from those defined above .
4. A luminescence energy transfer assay comprising a first group labelled with an energy donor and a second group labelled with an energy acceptor, wherein
- the acceptor is either a short excited state lifetime luminescent label or a non-luminescent label, and - and the increase or decrease, respectively, in energy transfer from the donor label to the acceptor label resulting from shortening or lengthening, respectively, of the distance between said labels, is measured characterized in that the donor is a luminescent lanthanide chelate, and
- the luminescent or non-luminescent label of the acceptor is attached to a solid carrier providing a large surface to which said second group is bound or can be bound via suitable covalent or non-covalent means .
5. The assay according to claim 4 characterized in that the luminescent or non-luminescent label molecules are in the solid carrier.
6. The assay according to claim 4 characterized in that the solid carrier is surface activated microbeads covalently coupled with the second group and with a plurality of acceptor molecules .
7. The assay according to claim 4 characterized in that the surface has been made by coating the microbeads with an adherent macromole such as a polylysine, agglutinin, lectin, antibody, which macromolecule either prior to or after the coating step is conjugated with the acceptor molecules .
8. A luminescence energy transfer assay comprising a first group labelled with an energy donor and a second group labelled with an energy acceptor, wherein
- the acceptor is either a short excited state lifetime luminescent label or a non-luminescent label, and
- and the increase or decrease, respectively, in energy transfer from the donor label to the acceptor label resulting from shortening or lengthening, respectively, of the distance between said labels, is measured characterized in that the donor is a luminescent lanthanide chelate, and - the acceptor is lipophilic compound anchored to a cell membrane or cell membrane fragment or the acceptor is made lipophilic by conjugating with a long chain hydrocarbon such as a fatty acid.
9. The assay according to any of the claims 2 - 8 characterized in that the luminescent lanthanide chelate has a long excited state lifetime and that it has one or more of the following properties:
- a high luminescence yield,
- an excited state lifetime of 1 ms or more, and - an emission distribution optimized for energy transfer.
10. The assay according to any of the claims 1 and 3 - 9 characterized in that the assay is based on a bioaffinity binding reaction.
11. The assay according to any of the claims 1 - 10 characterized in that the assay is based on an enzymatically catalyzed reaction.
12. The assay according to claim 11 characterized in that the reaction is a cleavage reaction.
13. The assay according to any of the foregoing claims characterized in that the lanthanide of the donor chelate is europium, terbium or samarium.
14. The assay according to claim 13 characterized in that the energy transfer is registered by a time-resolved fluorometer using a predeterminated instrumental setting avoiding cross talk or donor emission to the channel used for acceptor emission measurement when there is no energy transfer .
15. The assay according to claim 14 characterized in that the instrumental counting time window is optimized for the assay, having delay period long compared to the length of excitation pulses and the emission lifetime of the acceptor without energy transfer, and the counting window shorter than the decay of the donor in assays measuring decreased distances .
16. The assay according to any of the foregoing claims characterized in that the acceptor molecules are brought to the vicinity of specific binding reaction using suitable secondary affinity reactions, such as anti-receptor antibodies, use of biotinylated binding reagents and acceptor labeled avidin, lectins etc.
17. The assay according to any of the claims 1 - 9 or 11 - 16 characterized in that the acceptor is a spin label.
18. A luminescence energy transfer assay comprising a first group labelled with an energy donor and a second group labelled with an energy acceptor, wherein - the acceptor is either a short excited state lifetime luminescent label or a non-luminescent label, and - and the increase or decrease, respectively, in energy transfer from the donor label to the acceptor label resulting from shortening or lengthening, respectively, of the distance between said labels, is measured characterized in that the donor is a luminescent lanthanide chelate, and that the instrument used to measure energy transfer is able to follow multiple parameters simultaneously or consecutely, such as absorbances at the wavelenghts of excitation or emissions, luminescence of different durations, scattering and luminescence decay times, in order to monitor and correct any interferences the sample matrix may have to excitation, energy transfer or emissions.
19. The assay according to claim 18 characterized in that the instrument automatically corrects any attenuation of excitation the sample may cause by following simultaneously the absorbances of the samples diluted into assay mixture and correcting the emission readings according to excitation or emission attenuation by sample absorption.
20. The assay according to claim 18 characterized in that the measured acceptor signal is normalized by recording also the donor emission which can be compared to zero calibrator, the lowering of signal without concomitant increase in acceptor luminescence being recorded and corrected .
21. The assay according to claim 18 characterized in that the decay time of either donor or the acceptor is registered and used as the measuring parameter.
22. The assay according to claim 18 characterized in that the decay time of the donor or the acceptor is utilized in correction of sample interferences.
23. The assay according to claim 18 characterized in that it is a suitable combination of the measurements according to claims 19, 20, 21 or 22.
PCT/FI1997/000560 1996-10-04 1997-09-19 Homogenous luminescence energy transfer assays WO1998015830A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP10517208A JP2001502055A (en) 1996-10-04 1997-09-19 Homogeneous luminescence energy transfer assay
EP97919087A EP0929810A2 (en) 1996-10-04 1997-09-19 Homogenous luminescence energy transfer assays

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FI963989 1996-10-04
FI963989A FI963989L (en) 1996-10-04 1996-10-04 Homogeneous assay methods based on luminescence energy transfer

Publications (2)

Publication Number Publication Date
WO1998015830A2 true WO1998015830A2 (en) 1998-04-16
WO1998015830A3 WO1998015830A3 (en) 1998-06-18

Family

ID=8546810

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FI1997/000560 WO1998015830A2 (en) 1996-10-04 1997-09-19 Homogenous luminescence energy transfer assays

Country Status (4)

Country Link
EP (1) EP0929810A2 (en)
JP (1) JP2001502055A (en)
FI (1) FI963989L (en)
WO (1) WO1998015830A2 (en)

Cited By (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5998146A (en) * 1998-07-17 1999-12-07 Wallac Oy Homogeneous luminescence assay method based on energy transfer
WO2000039335A1 (en) * 1998-12-24 2000-07-06 Aclara Biosciences, Inc. Individually addressable solid surfaces for multiplexed operations
FR2792072A1 (en) * 1999-04-08 2000-10-13 Cis Bio Int HOMOGENEOUS METHOD OF DETECTING OR DETERMINING A CHEMICAL OR PHYSICOCHEMICAL INTERACTION
WO2001040805A1 (en) * 1999-11-30 2001-06-07 Akzo Nobel N.V. Steroid compounds for steroid receptor binding assays
WO2001092882A1 (en) * 2000-06-02 2001-12-06 Cis Bio International Method of detecting the presence of a liquid in a mix
WO2003076939A1 (en) * 2002-03-08 2003-09-18 Wallac Oy Dissociative fluorescence enhancement assay
EP1382965A4 (en) * 2001-04-23 2004-09-29 Eiken Chemical Analysis method using reporter (label) intermolecular interaction
WO2004086049A1 (en) * 2003-03-28 2004-10-07 Tero Soukka A homogeneous luminescence energy transfer bioassay
WO2005033709A1 (en) * 2003-10-01 2005-04-14 Wallac Oy Improved homogeneous time-resolved energy transfer assay
WO2005062048A1 (en) * 2003-12-01 2005-07-07 Dade Behring Marburg Gmbh Homogeneous detection method
WO2006042907A1 (en) * 2004-10-19 2006-04-27 Wallac Oy A novel probe and its use in bioaffinity assays
WO2006042912A1 (en) * 2004-10-22 2006-04-27 Wallac Oy Highly sensitive homogeneous assay based on anti-stokes' shift fret measurement
US7041459B2 (en) 2001-05-21 2006-05-09 Monogram Biosciences, Inc. Analyzing phosphorylated proteins
WO2006125855A1 (en) * 2005-05-24 2006-11-30 Hidex Oy Correction method and measurement device for anti-stokes photoluminescence measurement
US7160735B2 (en) 2000-04-28 2007-01-09 Monogram Biosciences, Inc. Tagged microparticle compositions and methods
WO2007077291A1 (en) 2005-12-30 2007-07-12 Turun Yliopisto Method for determination of concentration, charge or unit size of a substance
US7255999B2 (en) 2001-05-21 2007-08-14 Monogram Biosciences, Inc. Methods and compositions for analyzing proteins
EP1845376A1 (en) * 2005-01-28 2007-10-17 Shionogi Co., Ltd. Quantitative measurement method for recombinant protein
US7358052B2 (en) 2001-05-26 2008-04-15 Monogram Biosciences, Inc. Catalytic amplification of multiplexed assay signals
US7371544B2 (en) 2000-02-16 2008-05-13 Jussi Nurmi Homogenous method for the detection of a polynucleotide, with e.g. cleavable lanthanide chelate label
US7402397B2 (en) 2002-05-21 2008-07-22 Monogram Biosciences, Inc. Detecting and profiling molecular complexes
US7524974B2 (en) 2002-07-08 2009-04-28 Tetsuo Nagano Fluorescent probe
EP2053059A1 (en) 2007-10-26 2009-04-29 Sanofi-Aventis Complexes of TRPC domains and SESTD1 domains and methods and uses involving the same
US7541467B2 (en) 2004-01-09 2009-06-02 Shigenobu Yano Fluorescent zinc ion sensor
US7563582B2 (en) 2000-11-25 2009-07-21 Sanofi-Aventis Deutschland Gmbh Process for screening chemical compounds for modulating the interaction of an EVH1 domain and a process for detecting said interaction
US7569355B2 (en) 2003-03-28 2009-08-04 Tero Soukka Homogeneous luminescence energy transfer bioassay
US7696245B2 (en) 2003-03-28 2010-04-13 Sekisui Medical Co., Ltd. Fluorescent probe for zinc
US7771929B2 (en) 2000-04-28 2010-08-10 Monogram Biosciences, Inc. Tag library compounds, compositions, kits and methods of use
EP2226633A1 (en) 2009-03-06 2010-09-08 Charité - Universitätsmedizin Berlin Uses and methods for the identification of a cytoprotective compound involving gp130 or LIFRalpha
WO2010149780A1 (en) 2009-06-26 2010-12-29 Sanofi-Aventis Test system for measuring mest activity as well as methods and uses involving the same
WO2011054900A1 (en) 2009-11-06 2011-05-12 Sanofi-Aventis Methods and uses relating to the identification of compound involved in pain as well as methods of diagnosing algesia
EP2348130A1 (en) 2010-01-21 2011-07-27 Sanofi Methods and uses relating to the identification of compound involved in pain as well as methods of diagnosing algesia
EP2348129A1 (en) 2010-01-21 2011-07-27 Sanofi Methods and uses relating to the identification of compound involved in pain as well as methods of diagnosing algesia
EP2348128A1 (en) 2010-01-21 2011-07-27 Sanofi Methods and uses relating to the identification of compound involved in pain as well as methods of diagnosing algesia
WO2011113888A1 (en) 2010-03-18 2011-09-22 Sanofi-Aventis Methods and uses relating to the identification of compound involved in pain as well as methods of diagnosing algesia
WO2011113891A1 (en) 2010-03-18 2011-09-22 Sanofi-Aventis Methods and uses relating to the identification of compound involved in pain as well as methods of diagnosing algesia
WO2011113890A1 (en) 2010-03-18 2011-09-22 Sanofi Methods and uses relating to the identification of compound involved in pain as well as methods of diagnosing algesia
EP2390348A1 (en) 2010-05-25 2011-11-30 Sanofi Methods and uses relating to the identification of compound involved in pain as well as methods of diagnosing algesia
EP2390349A1 (en) 2010-05-25 2011-11-30 Sanofi Methods and uses relating to the identification of compound involved in pain as well as methods of diagnosing algesia
CN102353790A (en) * 2011-06-25 2012-02-15 南方医科大学 Homogeneous time-resolved fluorescence analysis method of alpha-fetalprotein
EP2532755A1 (en) 2011-06-10 2012-12-12 Sanofi-Aventis Methods and uses based on Slfn2 expression and relating to the identification and profiling of compounds for use in the treatment or prevention of pain
USRE44437E1 (en) 2003-04-01 2013-08-13 Monogram Biosciences, Inc. Methods for detecting receptor complexes comprising PI3K
US8652785B2 (en) 2008-12-04 2014-02-18 Sanofi Method of screening a modulator of endothelial NO synthase comprising the use of heme binding protein 1
CN104181310A (en) * 2014-07-30 2014-12-03 美艾利尔（上海）诊断产品有限公司 A time-resolved immunofluorescence kit for detecting β-hCG content and its preparation method and application
US9736555B2 (en) 2013-04-15 2017-08-15 Wallac Oy Method and a device for cross-talk correction of measured intensities
US9816926B2 (en) 2012-06-22 2017-11-14 Macquarie University Multiplex suspension assay/array using lifetime coding
WO2021148717A1 (en) 2020-01-20 2021-07-29 Iptomics Oy Luminescence hybridisation assay method
US11112403B2 (en) 2019-12-04 2021-09-07 Progenity, Inc. Assessment of preeclampsia using assays for free and dissociated placental growth factor
US11333672B2 (en) 2017-09-13 2022-05-17 Progenity, Inc. Preeclampsia biomarkers and related systems and methods

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001255326A (en) * 2000-01-31 2001-09-21 Pen State Res Found:The Inquiries about changes in the contents of sealed containers
US7537938B2 (en) 2000-04-28 2009-05-26 Monogram Biosciences, Inc. Biomarker detection in circulating cells
JPWO2007125822A1 (en) * 2006-04-28 2009-09-10 国立大学法人東京工業大学 Complex for drug screening
EP1933151A1 (en) 2006-12-15 2008-06-18 F. Hoffmann-La Roche Ag Assays for measuring phosphate modification enzyme activity
CN102639998B (en) * 2009-04-30 2014-12-03 Cis-生物国际公司 Method for detecting compounds modulating dimers of VFT domain membrane proteins

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4996143A (en) * 1985-12-23 1991-02-26 Syngene, Inc. Fluorescent stokes shift probes for polynucleotide hybridization
US4868103A (en) * 1986-02-19 1989-09-19 Enzo Biochem, Inc. Analyte detection by means of energy transfer
EP0272320B1 (en) * 1986-06-17 1994-03-23 Baxter Diagnostics Inc. Homogeneous fluoroassay methods employing fluorescent background rejection
US5194300A (en) * 1987-07-15 1993-03-16 Cheung Sau W Methods of making fluorescent microspheres
GB8820887D0 (en) * 1988-09-06 1988-10-05 Atomic Energy Authority Uk Detecting selected species
US5326692B1 (en) * 1992-05-13 1996-04-30 Molecular Probes Inc Fluorescent microparticles with controllable enhanced stokes shift
FR2664702B1 (en) * 1990-07-13 1993-08-06 Cis Bio Int METHOD FOR REDUCING INTERFERENCE IN A FLUORESCENCE ASSAY.
FR2664699B1 (en) * 1990-07-13 1995-08-18 Cis Bio Int METHOD FOR AMPLIFYING THE EMISSION SIGNAL OF A LUMINESCENT COMPOUND.
US5457186A (en) * 1993-10-13 1995-10-10 Wallac Oy Luminescent lanthanide chelates with decreased non-radiative energy loss
US5622821A (en) * 1994-06-29 1997-04-22 The Regents Of The University Of California Luminescent lanthanide chelates and methods of use
FI96367C (en) * 1994-10-17 1996-06-10 Erkki Juhani Soini Biospecific assay method
US5741657A (en) * 1995-03-20 1998-04-21 The Regents Of The University Of California Fluorogenic substrates for β-lactamase and methods of use

Cited By (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0973036A3 (en) * 1998-07-17 2000-03-08 Wallac Oy Homogeneous luminescence assay method based on energy transfer
US5998146A (en) * 1998-07-17 1999-12-07 Wallac Oy Homogeneous luminescence assay method based on energy transfer
WO2000039335A1 (en) * 1998-12-24 2000-07-06 Aclara Biosciences, Inc. Individually addressable solid surfaces for multiplexed operations
FR2792072A1 (en) * 1999-04-08 2000-10-13 Cis Bio Int HOMOGENEOUS METHOD OF DETECTING OR DETERMINING A CHEMICAL OR PHYSICOCHEMICAL INTERACTION
WO2000062072A1 (en) * 1999-04-08 2000-10-19 Cis Bio International Homogeneous detection and/or determination method for a chemical or physico-chemical interaction
US6878552B1 (en) * 1999-04-08 2005-04-12 Cis Bio International French Joint Stock Company Homogeneous detection and/or determination method for a chemical or physico-chemical interaction
WO2001040805A1 (en) * 1999-11-30 2001-06-07 Akzo Nobel N.V. Steroid compounds for steroid receptor binding assays
US7371544B2 (en) 2000-02-16 2008-05-13 Jussi Nurmi Homogenous method for the detection of a polynucleotide, with e.g. cleavable lanthanide chelate label
US7160735B2 (en) 2000-04-28 2007-01-09 Monogram Biosciences, Inc. Tagged microparticle compositions and methods
US7771929B2 (en) 2000-04-28 2010-08-10 Monogram Biosciences, Inc. Tag library compounds, compositions, kits and methods of use
FR2809817A1 (en) * 2000-06-02 2001-12-07 Cis Bio Int METHOD FOR DETECTING THE PRESENCE OF A LIQUID IN A MIXTURE
WO2001092882A1 (en) * 2000-06-02 2001-12-06 Cis Bio International Method of detecting the presence of a liquid in a mix
US6952259B2 (en) 2000-06-02 2005-10-04 Cis Bio International Method of detecting the presence of a liquid in a mix
EP1405079B1 (en) * 2000-11-25 2012-05-30 Sanofi-Aventis Deutschland GmbH Modulation of the interaction between evh1 domains
US7563582B2 (en) 2000-11-25 2009-07-21 Sanofi-Aventis Deutschland Gmbh Process for screening chemical compounds for modulating the interaction of an EVH1 domain and a process for detecting said interaction
US7595202B2 (en) 2001-04-23 2009-09-29 Teruyuki Nagamune Analysis method using reporter (label) intermolecular interaction
EP1382965A4 (en) * 2001-04-23 2004-09-29 Eiken Chemical Analysis method using reporter (label) intermolecular interaction
US7255999B2 (en) 2001-05-21 2007-08-14 Monogram Biosciences, Inc. Methods and compositions for analyzing proteins
US9939447B2 (en) 2001-05-21 2018-04-10 Monogram Biosciences, Inc. Methods and compositions for analyzing proteins
US7041459B2 (en) 2001-05-21 2006-05-09 Monogram Biosciences, Inc. Analyzing phosphorylated proteins
US7358052B2 (en) 2001-05-26 2008-04-15 Monogram Biosciences, Inc. Catalytic amplification of multiplexed assay signals
US7211440B2 (en) 2002-03-08 2007-05-01 Wallac Oy Dissociative fluorescence enhancement assay
US7381567B2 (en) 2002-03-08 2008-06-03 Wallac Oy Dissociative fluorescence enhancement assay
WO2003076939A1 (en) * 2002-03-08 2003-09-18 Wallac Oy Dissociative fluorescence enhancement assay
CN100350250C (en) * 2002-03-08 2007-11-21 沃拉克有限公司 Dissociative fluorescence enhancement assay
US7402397B2 (en) 2002-05-21 2008-07-22 Monogram Biosciences, Inc. Detecting and profiling molecular complexes
US7524974B2 (en) 2002-07-08 2009-04-28 Tetsuo Nagano Fluorescent probe
US7696245B2 (en) 2003-03-28 2010-04-13 Sekisui Medical Co., Ltd. Fluorescent probe for zinc
US7569355B2 (en) 2003-03-28 2009-08-04 Tero Soukka Homogeneous luminescence energy transfer bioassay
WO2004086049A1 (en) * 2003-03-28 2004-10-07 Tero Soukka A homogeneous luminescence energy transfer bioassay
USRE44437E1 (en) 2003-04-01 2013-08-13 Monogram Biosciences, Inc. Methods for detecting receptor complexes comprising PI3K
US7846658B2 (en) 2003-10-01 2010-12-07 Wallac Oy Homogeneous time-resolved energy transfer assay
WO2005033709A1 (en) * 2003-10-01 2005-04-14 Wallac Oy Improved homogeneous time-resolved energy transfer assay
US8399209B2 (en) 2003-12-01 2013-03-19 Siemens Healthcare Diagnostics Products Gmbh Homogeneous detection method
US8628933B2 (en) 2003-12-01 2014-01-14 Siemens Healthcare Diagnostics Products Gmbh Homogeneous detection method
WO2005062048A1 (en) * 2003-12-01 2005-07-07 Dade Behring Marburg Gmbh Homogeneous detection method
US7541467B2 (en) 2004-01-09 2009-06-02 Shigenobu Yano Fluorescent zinc ion sensor
WO2006042907A1 (en) * 2004-10-19 2006-04-27 Wallac Oy A novel probe and its use in bioaffinity assays
GB2433993B (en) * 2004-10-19 2010-04-28 Wallac Oy Single molecule TR-FRET probe
GB2433993A (en) * 2004-10-19 2007-07-11 Wallac Oy A novel probe and its use in bioaffinity assays
WO2006042912A1 (en) * 2004-10-22 2006-04-27 Wallac Oy Highly sensitive homogeneous assay based on anti-stokes' shift fret measurement
GB2433994A (en) * 2004-10-22 2007-07-11 Wallac Oy Highly sensitive homogeneous assay based on anti-stokes' shift fret measurement
EP1845376A1 (en) * 2005-01-28 2007-10-17 Shionogi Co., Ltd. Quantitative measurement method for recombinant protein
EP1845376A4 (en) * 2005-01-28 2008-07-09 Shionogi & Co Quantitative measurement method for recombinant protein
WO2006125855A1 (en) * 2005-05-24 2006-11-30 Hidex Oy Correction method and measurement device for anti-stokes photoluminescence measurement
US7826052B2 (en) 2005-05-24 2010-11-02 Hidex Oy Correction method and measurement device for anti-stokes photoluminescence measurement
WO2007077291A1 (en) 2005-12-30 2007-07-12 Turun Yliopisto Method for determination of concentration, charge or unit size of a substance
EP2053059A1 (en) 2007-10-26 2009-04-29 Sanofi-Aventis Complexes of TRPC domains and SESTD1 domains and methods and uses involving the same
US8652785B2 (en) 2008-12-04 2014-02-18 Sanofi Method of screening a modulator of endothelial NO synthase comprising the use of heme binding protein 1
EP2226633A1 (en) 2009-03-06 2010-09-08 Charité - Universitätsmedizin Berlin Uses and methods for the identification of a cytoprotective compound involving gp130 or LIFRalpha
WO2010099979A2 (en) 2009-03-06 2010-09-10 Charité - Universitätsmedizin Berlin Gliedkörperschaft Der Freien Universität Berlin Und Der Humboldt-Universität Berlin Uses and methods for the identification of a cytoprotective compound involving gp130 or lifralpha
EP2267152A1 (en) 2009-06-26 2010-12-29 Sanofi-Aventis Test system for measuring MEST activity as well as methods and uses involving the same
WO2010149780A1 (en) 2009-06-26 2010-12-29 Sanofi-Aventis Test system for measuring mest activity as well as methods and uses involving the same
WO2011054900A1 (en) 2009-11-06 2011-05-12 Sanofi-Aventis Methods and uses relating to the identification of compound involved in pain as well as methods of diagnosing algesia
WO2011089194A1 (en) 2010-01-21 2011-07-28 Sanofi-Aventis Methods and uses relating to the identification of compound involved in pain as well as methods of diagnosing algesia
EP2348129A1 (en) 2010-01-21 2011-07-27 Sanofi Methods and uses relating to the identification of compound involved in pain as well as methods of diagnosing algesia
EP2348130A1 (en) 2010-01-21 2011-07-27 Sanofi Methods and uses relating to the identification of compound involved in pain as well as methods of diagnosing algesia
EP2348128A1 (en) 2010-01-21 2011-07-27 Sanofi Methods and uses relating to the identification of compound involved in pain as well as methods of diagnosing algesia
WO2012052189A1 (en) 2010-01-21 2012-04-26 Sanofi-Aventis Methods and uses relating to the identification of compound involved in pain as well as methods of diagnosing algesia
WO2011089192A1 (en) 2010-01-21 2011-07-28 Sanofi-Aventis Methods and uses relating to the identification of compound involved in pain as well as methods of diagnosing algesia
WO2011113888A1 (en) 2010-03-18 2011-09-22 Sanofi-Aventis Methods and uses relating to the identification of compound involved in pain as well as methods of diagnosing algesia
US8673823B2 (en) 2010-03-18 2014-03-18 Sanofi Methods and uses relating to the identification of compound involved in pain as well as methods of diagnosing algesia
WO2011113890A1 (en) 2010-03-18 2011-09-22 Sanofi Methods and uses relating to the identification of compound involved in pain as well as methods of diagnosing algesia
WO2011113891A1 (en) 2010-03-18 2011-09-22 Sanofi-Aventis Methods and uses relating to the identification of compound involved in pain as well as methods of diagnosing algesia
WO2011147851A1 (en) 2010-05-25 2011-12-01 Sanofi-Aventis Methods and uses relating to the identification of compound involved in pain as well as methods of diagnosing algesia
WO2011147850A1 (en) 2010-05-25 2011-12-01 Sanofi-Aventis Methods and uses relating to the identification of compound involved in pain as well as methods of diagnosing algesia
EP2390349A1 (en) 2010-05-25 2011-11-30 Sanofi Methods and uses relating to the identification of compound involved in pain as well as methods of diagnosing algesia
EP2390348A1 (en) 2010-05-25 2011-11-30 Sanofi Methods and uses relating to the identification of compound involved in pain as well as methods of diagnosing algesia
WO2012168452A1 (en) 2011-06-10 2012-12-13 Sanofi Methods and uses based on slfn2 expression and relating to the identification and profiling of compounds for use in the treatment or prevention of pain
EP2532755A1 (en) 2011-06-10 2012-12-12 Sanofi-Aventis Methods and uses based on Slfn2 expression and relating to the identification and profiling of compounds for use in the treatment or prevention of pain
CN102353790A (en) * 2011-06-25 2012-02-15 南方医科大学 Homogeneous time-resolved fluorescence analysis method of alpha-fetalprotein
US9816926B2 (en) 2012-06-22 2017-11-14 Macquarie University Multiplex suspension assay/array using lifetime coding
US9736555B2 (en) 2013-04-15 2017-08-15 Wallac Oy Method and a device for cross-talk correction of measured intensities
CN104181310A (en) * 2014-07-30 2014-12-03 美艾利尔（上海）诊断产品有限公司 A time-resolved immunofluorescence kit for detecting β-hCG content and its preparation method and application
US11333672B2 (en) 2017-09-13 2022-05-17 Progenity, Inc. Preeclampsia biomarkers and related systems and methods
US11112403B2 (en) 2019-12-04 2021-09-07 Progenity, Inc. Assessment of preeclampsia using assays for free and dissociated placental growth factor
US11327071B2 (en) 2019-12-04 2022-05-10 Progenity, Inc. Assessment of preeclampsia using assays for free and dissociated placental growth factor
WO2021148717A1 (en) 2020-01-20 2021-07-29 Iptomics Oy Luminescence hybridisation assay method

Also Published As

Publication number Publication date
JP2001502055A (en) 2001-02-13
FI963989L (en) 1998-04-05
FI963989A0 (en) 1996-10-04
WO1998015830A3 (en) 1998-06-18
EP0929810A2 (en) 1999-07-21

Similar Documents

Publication Publication Date Title
WO1998015830A2 (en) Homogenous luminescence energy transfer assays
EP0973036B1 (en) Homogeneous luminescence assay method based on energy transfer
Yuan et al. Lanthanide complex-based fluorescence label for time-resolved fluorescence bioassay
EP2703816B1 (en) Biosensor for detecting multiple epitopes on a target
Hemmilá et al. Time-resolution in fluorometry technologies, labels, and applications in bioanalytical assays
AU688928B2 (en) Luminescent lanthanide chelates and methods of use
US7826052B2 (en) Correction method and measurement device for anti-stokes photoluminescence measurement
JP5841525B2 (en) Fluorescence assay
US6908769B2 (en) Dye pair for fluorescence resonance energy transfer (FRET) measurements
EP2118658B1 (en) Improved homogeneous luminescence bioassay
Deshpande Principles and applications of luminescence spectroscopy
WO1991000511A1 (en) Detecting or quantifying multiple analytes using labelling techniques
Motson et al. Potential applications for the use of lanthanide complexes as luminescent biolabels
EP1957670B1 (en) Homogeneous luminescence bioassay
O'Riordan et al. Monofunctional derivatives of coproporphyrins for phosphorescent labeling of proteins and binding assays
Kolb et al. Homogeneous, time-resolved fluorescence method for drug discovery
Selvin Lanthanide-labeled DNA
Kokko et al. Particulate and soluble Eu (III)-chelates as donor labels in homogeneous fluorescence resonance energy transfer based immunoassay
Wolfbeis et al. Advanced luminescent labels, probes and beads and their application to luminescence bioassay and imaging
US6951760B2 (en) Diagnostic neodymium(III), ytterbium(III), or erbium(III) ion-ligand complexes
US20060115842A1 (en) Highly sensitive homogeneous assay based on anti-Stokes' shift FRET measurement
Kokko Lanthanide Chelates as donors in fluorescence resonance energy transfer: exciting prospects for bioaffinity assay detection
Kolb¹ et al. Homogeneous, Time-Resolved

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

AK Designated states

Kind code of ref document: A3

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1997919087

Country of ref document: EP

ENP Entry into the national phase

Ref country code: JP

Ref document number: 1998 517208

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 09180854

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1997919087

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1997919087

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载